var title_f18_59_19376="Testes in phenotypic female";
var content_f18_59_19376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perineoscrotal hypospadias with palpable gonads",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient had a 46,XY karyotype, micropenis, palpable testes, perineoscrotal hypospadias, and a bifid scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Christopher P Houk, MD and Lynne L Levitsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19376=[""].join("\n");
var outline_f18_59_19376=null;
var title_f18_59_19377="Holoprosencephaly and normal";
var content_f18_59_19377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Holoprosencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 273px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAERAZgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAK+dvAvj/xZNP4LsNbu3lOr3ouI7sIoE9th0eJsDgq6qeOcMK+iazotC0iKOyji0uwSOxYtaqtugFuT1MYx8pPtiumhWhTjJTje/wCGj/4BEottWZ5fZ/FjUZLH7fLp9ibe707UL61hilYy25tQTtn7DdjqMYPFaN1438Tx2vhpU0zRlvdeSaaANcytHHGlusoLnYDuPzZABHQZ6mu9TQNGSW9lTSdPWS+VkunFsgNwrfeEhx8wPcHNTtpWnsbMtY2hNmpS2JhX9wpXaQnHygrxx24qnWo3uof10/ryFyy7nluhfFPUbm2muNXs9Ms7eTQG1m2kWSRwhVxHtk+XOCxB+UEgccnmso/ETW9YubOynRbGe11/SonktWZBPBcFyVZSxIGE5BPOegr2CLQNHiQLFpOnootzaALbIAICcmLp9wnnb0qG08LeH7MAWehaVABJHMPKs41w8eSjcDquTg9Rk4q1XoJtqAuWXc2aKKK4TUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAw/HV5cad4I8Q3tlIYrq2064mikABKOsTFTzxwQK8j034jeJLe60G51ayuo7RfDUuoyRmSJv7QdIgwlGzJQHrg4xnpXudzBDd20tvdRRzQSoY5IpFDK6kYKkHggjjBqtHo+mRyW0kenWaSW0P2eBlgUGKLGNinHyrgDgcV00a1OEXGcb/8ADESi29GePeJfiBrVz4P12Fntbe/t7fTr2K70uZiqpPOgMZJ5DYz35B6Cuim+It8niprUWdn/AGautpoZiMjC7LsgbzgvTy+enoCc128PhvQ4LCayh0bTY7KdxJLbpaoI5GBBBZQMEggHJ7irB0fTDqo1Q6dZnUgu0XZgXzgMYxvxnGOOtW69Fq3J3/Jf5C5ZdzyzTPirqk8GnXVxYaaYNQtdQljihlYyxNahzukB6I2zHHcjnnFaA8eeIXsPC5ey0S0uvEETXNvLLcyNDFEsCyESHapDsWwACQADycV1XhXwNoPhrTWs7KxhmaRZI5rieGNpp0d2Yo7BRuX5sYPYCta70TSrzTYdPvNMsZ7CEKIraW3RoowowoVCMDA4GBxTnVoc3uw0/wCH/wCB9wKMras8pvPi9qIsdF1BNMtrPTru0juLi4uPMmWJ2kKbSI/mReMhyDnIwK0dP+JerX3iq6tYtIh/sqC+nsHYuRLG0YOHYk45I+6BkA9TXoVx4d0W5u7a6uNH06W5tVVYJntkZ4gvQKSMqB2xSyeH9Gl1P+0pNI099R6famtkMvTH38Z6e9DrULaQ7hyy7nllr8WNZt9OtNT1bR7FrO+0ifUraO0mcyAxYyrlhgA57Zx74q/rHxC1vSNN04zx6Fd3mpTRJA1nK7xwh0ZvnGcknbhcEbuemOfR4dE0qAWwg0yxj+zRtDBst0HlI33lXA+VT3A4NV4/C3h+Kyns4tC0pLO4YPNAtnGI5GHQsuME+5o9tQvfk/r+vvDll3PNpPifr3k+W2m6VY3sOkT6lOLudtm6KYxlFx/eABAOCCec45zLj4h+IbK98Ua/ZwQTaVbWWlXkljeTOGgWaMlliAGNxLck4+6OD29Ik+H3hqXXLbUZNLtGS2tDZw2Rt4jbIpk8zeI9vD5zyD0J4rcudE0q6+2fadMsZvtoRbrzIEbzwn3A+R8wXtnOO1V7fDx2hv8A5r9Bcsn1PPL74k3tv4+g0mC3s7rSn1RNKeVA6yRSsmTkk4JB6gLjH8Wa53Q/iZqnh74feGbrVIH1N9TsbjyJ3dmklvFlISNj6MCOevFewSeHNEl1P+0pNH019R3rJ9qa1Qy7lGFbfjOQOhzxVHUvBukXzaEvk/ZrTRrn7XbWdsiRw+YAdpKhexJIxjk96Ua1Cyi4dr/JP9WDjLe5u2ZnNpCbtUW5KKZVjOVD45A9s1NRRXCahRRRQAUUUUAFFFFABRRRQAUUUUAFFFMmljhQvNIkaDqzMABQA+iqn9p2H/P9a/8Af1f8afDfWk77IbqCRuuEkBP6UAWKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKR2VFLOQqgZJJwAKAForz3W/jH4J0q5e1TVv7RvEO02+mxNdPn0+QEZ/GszT/iP4v1otJofwy1Q2hGYptRvY7Mt9UYEj86APVaK8kuPEvxfbabfwDo0Yz8wk1ZXP6Y/rUR+JPj3TnkGt/C3UGjQnMmnXqTjAHYY5oA9goryjTPjx4RknhtddGpeHr6Q7TDqlo8QU+7cjHvXpum6jZapapc6bd293btyssEgdT+IoAtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVzPjrxxofgmyhn1y5ZZLhtlvbQoZJp2/uog5PbnpyKAOmJwMngV574i+LPh/TtTfSdHW78Ra2OPsWkxGcqemHcfKnvk8ViRaN4v+JieZ4saTw14VkOV0i1ci8uU7efKPuD1Reexr0fw14b0fwxpyWOgadbWFsoA2wpgt7serH3JNAHAHTvid4s/eXuq2Xg3TpMFbWzjF1eKPRpD8gP+7SL8DfDl5dC68UajrviO44ydRvmKfgq7Rj2r1aigDzdPgf8ADlWDDwvaZHrJIR+W6pLv4K/D64iCDw3bW5AwJLZ3icf8CVga9EooA8vf4SyWOW8LeNfFOkPxtR7v7VCOf7kgJP51Gb34oeE5d2oWen+MtJU/NLYqLW9C+vlk7GPsOa9UooA5rwj420TxSJI9OuHh1CH/AF+n3aGG6gPo8bc/iMj3rpa5jxn4I0bxZHG99C8GpQc2uo2rGK5t27FXHP4HIPpXFjxP4l+G92lv4+kbWfDMjBIvEFvDtktj2FzGvQf7Y49etAHrdFQ2d1Be2sNzaTRz28yh45I2DK6noQR1FTUAFFFFABXn/wAdbjWbX4bahLoD3ccwkiFxLZ58+O3LjzWjxzkLnkcgZPavQKKAPlLxxewLofj+PwJf3l14JTRLZ3lNxLNFHf8A2lBtjdyTkx8sAevWuj1zUL7QvH/xU8SXOpTyS6Qtja2hS1EhtlnSNsqGbaqgFgxIxzuPTB+iqKAPm/Q/ip4nvNMji1HWLC0shrctjc+Ikt1mjt4RAJI84AQl2O0PgL7d6sr4v8Q2Xj7Ubi08Tf20knhs3umWP2Vo4tSkRZf9VHu4bKbyVGWHyjjBr6E82PzvK3r5u3dsz82OmcelPoA+df8AhaPiaHwd4kv7DVLTWFsrbTZotR+xiNIbiedElt2UcMVDZ9Vzg81veM/Ffjnwt4n0rw2bu01G78QIkdhfx2PlRwTC4Hnbo97EqsDA8seRmvbKy7zw/pl74g07W7q28zU9PjkjtZjI2IlkAD4XO3JAAzjOKAOO+MPiu88LJ4ZFrqdtplvqGo/Zbu8uYg6xReU7FuSACCo56V5vo3i/WNQ8QeFtb1ZpppYdK1t4pre2IN5FEV8uZYcjJYAELxntjNe96voWnaxdabcajb+dNptwLq1bey+XLtK7sAjPDHg5FaVAHzHonxf8W3Gna4YL211CNLazuYrz7OsrWMcsuyV5EiADbF5K87T1JwRW94g+IuqWMFoth40sp9KeO8kXXv7OUpNPGqGO1AHyEks3K/e+6OQa9+ooA+WPi7488Qap4S1aw127j8OudEsLuLTfIxJfyykNLtduUEZGNo5HeuxufiL4pX4uPo0lzp9jZxavFZJp10qo9zavtHnIfvuxLEjb8oxg+te7UUAFFMnmjt4ZJp5EjijUs7ucKoHUknoK8nn1XW/irLLaeF7ibRvBeDHcavsxcX/OGS3z91OCDJ3zxQBqeIvirYwatLovhHTbzxTrsbbJILAYhgP/AE1mPyr+v4VRTwP4j8blZ/iZfpb6eDlNA0qVlgI/6bS/ekPsMLXfeFfDekeFdHh0zQLGKzs4hwqDlj/eY9WPua16AM3Q9C0rQbNbXRNOtLC3UAbLeIID9cdfxrSoooAKKKKAKeq6XYavatbapZW15bsMGOeIOp/A15xqfwW0OG4a/wDBd5f+E9U6iXTZSImPYPEflYe3Fep0UAeNv458X/DuWGD4laemqaKx2DX9KjJ8v/rtF1X6jj0zXq2i6vp+uabDqGj3sF7ZSjKTQOGU/iO/tVx0WRGR1DIwwVIyCPSvH/EHgPWfA+oT+IvhQFCSMZL/AMPSMfIu+eTFn/Vv16f/AFiAexUVzPgDxnpnjfQl1HSy8ciN5V1aSjbLayj70br2I/WumoAKKKKACiiigAooooAKKK5T4ieLD4Y0uCOxgF5r2oy/ZdMs/wDntMe7eiKPmY9gPcUAU/iD45/sCe30bQbUat4svh/ouno2AinjzZT/AARjuTjPQVU8B/D19M1P/hJPFt++t+LpU2tcyf6q1U/8s4E6Ko6Z6nnpnFavw/8ABsXhi3uLq8nbUPEGoN5uoajJ96Z/7q/3Y16Ko6CutoAKKKKACiiigAooooAKKKKACorq3hu7aW3uokmglUpJG65V1PBBB6ipaKAPCSlz8DPEJkVp7j4a6jKAynLtpMzZ5Hfyz/nnr7lazw3VvFcW0iSwSqHSRDlWB6EGo9RsrbUrGeyv4I7i0nQxyxSLuV1PUEV454Vu7z4SeKE8K65I8ngvUZyNE1ByWFpIxz9mkY9B/dJ/xwAe10UUUAFFFFABVe/uGtbK4njhe4kjjZ0hQjdIQCQoz3OMVYryfRbDWvG/xNk1/Wre90zw94fmeDTLGYGNrmfGGuGH93nC9f50AaHwq8M6qL2+8ZeMVZPE2rLsFtvJSwts5SBR0z3J9fxr0iiigAooooAKKKKACiiigAoorz74j6lqGp6tp/gnw9cvaahqUbXF7ep96zslIV2X/bYnavpye1AGBeNN8XfElzp8Eskfw/0uby7p1G06pdI3MQP/ADxXjP8AeP6euW8EVtBHBbRJDDGoRI41CqoHQADgCqmg6PYaBo9rpekWyW1jbII4o0HAHqfUnqT3NX6ACiiigAooooAKKKKACiiigAooooA8i+J2hXPhDW/+Fj+EoHa6hAGt2ERwt9aj7z4/56IOc/5Ppnh3WrDxFolnq2kXC3FjdxiSOQeh7EdiOhHY1oMoZSrAFSMEEZBFeIeE8/Cr4s3HhaVvL8KeJXa70onhbe5/jhz2zxgf7vqaAPcKKKKACiiigAooooAK828EI3i3x5qvjKbLabZh9J0YdmRW/fzj/eddoPotaXxj1m60nwPcw6WcarqckemWXOD5szbMj6Asc+1dJ4Z0a18O+HtO0ewTZa2UCwoPUAdfqTz+NAGnRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWB478L2PjLwrf6HqaZhuUwr943HKuPcHBrfooA82+B/iu51rQLrRNdYDxJ4flNhfL3cLwkv0YD8wa9Jrxn4qWsngHxpp/wASNKVRZSsmn69CBw8LMAs3+8pwM/T3r2VHWRFdCGVhkEdxQAtFFed/Ffxdf6d9j8MeEgJvF+sZS2GNy2kX8dxJ1wqjpnqfpQBieOL3UvH/AI4TwV4duriy0nTHjudd1CFijZzuS2Qj+I9T/wDWwfXlUKoUdAMc1Q0Kwk07S7aG6n+13qxotxdMgVp3CgF2x3OK0KACiiigAooooAKKKKACiiigBk8sdvDJNM6xxRqXd2OAoAySa87+DkMurR6v41vwTc6/cFrUN1isoyVhQegIy/vuzU/xtu7j/hD49D084v8AxDdRaVEQ2CqyH9434IG57cV3Gm2UGnafa2VogS3tolhjUdlUAAfkKALFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcF8bfCknirwJdJp6sNa09hf6dIg+dZ4+QB9RkfjXe0UAcp8LvFkXjXwRpusoAlxInl3UXQxTrw6kduefoRXV1494ZQ+B/jnq2gqBHo3iiE6pZqMBUuU4mUfUfNj6V7DQAUUUUAFFFFAHm/jVF1j4t+B9Icb4bFLnWJl9GUCOIn/gTt+VekV53ozPffHXxJNsBi07R7S0DkfxSO8hAP0Az+FeiUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGV4q0S38R+G9S0a9ANvfQPA3HTI4P1Bwfwri/gBrF1qHw/h03VSRq2hTPpV2rZ3AxHCk/Vdtek15Rprjwd8W/G91dhrfw9e6bDrE1y/EUUqFo3/FgM4HPFAHYfEXxjZeCPDcup3itNO7CC0tU+/cztwsaj3PX0Gal8LaYsgh8Q6to9rYeJ720jjvDG28oByI93oP85xWFp3hzTvGHinSPHs95Pe2K2aPpVjPDsS2ZuTNg8lyMdRx+WO/oAKKKKACiiigAooooAKKKKACiiigDzi8A1z46WEBG638OaW9yc8gT3DbF/EIjf8AfVej1518LI2uPFXxF1SVWEk2tfYwW5ykEKKpB9PmPHavRaACiiigAooooAKKKKACiiigAooooAKKKKACiiigDy3497NMsPDHijAV9D1m3ld8ciGQ+XIM+4Yce1epVwvx004an8IfFcBUMUsJLhc9jGPMz/47XQ+DLpr3wfoV07BnnsYJGI6EmNSaANmiiigAooooA4LwB5Mnjn4hTRDMn9owQu3P8NtGcf8Ajx/Ou9rgvh9sh8b/ABCtVeQt/aMFwVboA9tGOPxQ13tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4H471cfEL4vaD4HmSYeE1El1cSIf3eoyRDdsDDgopwD759BXffEp9W8RWb+GfB+oWkN7NIkWqTrOvnWNs4OWCddzAEDpXHeIPD1h4S+KHwh07Qka2tIFvrVUBzuXygxJPck8k0Ae2xoscaxxqqIoCqqjAAHQAU6iigAooooAKKKKACiiigAooooAKKKKAPPPgXJ9o8E3FyzB5J9W1CR5BzvP2mQA578AD8K9Drzj4AqqfD3amNi6nfgY6Y+1S16PQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcz8Uf+SaeLf+wRd/8Aol6p/Bp0k+FHhNo2DL/ZsAyPZADVn4qypD8MfFryOEUaTdDJOOTEwH61D8ILVrP4W+FIHjMbLpsBKnsSgP8AWgDr6KKKACiiigDhtILWXxj8RWxIZdQ0u0vV5+6Y3kiI/HIrua878aSR6J8UfBmstIqLqPnaJMDxu3DzYvyZCP8AgVehSNsjZ8M20E4UZJ+lAHL/ABA8eaH4F0w3WtXJ85kZobSFd802P7qjtkjk4Az1riJPin4sWWGRfhxfmzMYmmzex+bAh6GQYwpI5wTnHXFaXhLTtP8AEHhK88XeJoElu9UQ3ExOf3FvFIXjhGegGwFh3bOc8Vvz+M7Z7O+Mdg9w8cttapDvX9/NOisIwenCupJ+vpQBZ8A+MbXxlpU15bWd3ZGKdrdo7lANzL3RhkOuD1Brp65DxVosy6ra67plsLzVLUMIftl+8NtaoUIc7VBBLDjofXgCr3h7xdpeuajNp9pcwSXkNulw4gmWWNlYlTsdfvbWBU9Occc0AdDRRRQAUUUUAFFFY/i7xHpvhPw9eazrU6wWVshZj3c9lUd2J4AoAm8Qa7pfh3TX1DW76Cys04MkrYyewA6kn0HNcT/wnniHVbhT4X8IyS2TnEM2q3QsXuOMl44mUsUHGSQDz0rB+Helax45vNR8TfEPQYYrW6iK6XDPIWktoG/uxdEYjkv98k8YHFem6FNpJ0eyaxuUnt7aDbFLK26RUUbW3FvmB4wc8560AcXB4z8YWaXN7rOgaPdaVZyGO8bR9Qeee2x94mNkXdtHJAOcdAa6vxBrU7+GZp/CZs9Q1a4tvO0+Fp1VZs4w/J5UZyfyrn9d+Knh3w54RTW9bLQNKkb/AGWNd7u0ilkUdjlVJz6Vh/BLwhM00vjfXLeK3vtSj/4lthEcxadZsd6og6AtnccevbJoA6j4V+Bo/Beiy/apvtuvag/2nU75uWmlPUA/3RkgD/GsTxTbpf8Ax/8ABSo297DTb26lTqEVtqK34nI/CvQPEOtaf4d0a61XWLlLWxtkLySueg9B6k9AO5rzP4JXaeNdc8R/EN4zGt9INNsInYForaLruHYs5JI9hQB67RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHm/wJhks/DGs6dKFBsdcvoFVRjaplLgY/wCB/livSK8z8BgaT8XPiBpDkKLxrXVrdcY3K8eyRv8AvtMV6ZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAebftETunwk1m1gLfadQMNjCqnlnklVcfiM13+k2i6fpdnZrt228KQjaMDCqBwPwrzD4pmTXPih8PfDEeTAly+tXYDYwsA/d59t5P5V6zQAUUUUAFFFFAHkHjnQ/+FheKtesm3eR4dsF+xOjfc1GT94HGO6KqDB/vn1r0fwhqp1rwppOpyFfMubWOWTbwA5Ubh+BzXzv8DfHN9cftCeNdImm86x1O6uZUAOVV4WKqw+qDH4CvX/gbKbv4ZWaznzFFxeRDIxlRcygA/hQBR+J/iK0TUIrD7XLAttEft42kKLW5R4Vnz0ZUcruPbOa8Q0D4q2dlrTw3a7rywup9RcFwySypYCBQGHU+YhII4Iaup+IVroB8LTJrV99q0q0c2Vm5kkt9VsGdsfZ5ECkyRcDqM4wQG4NeSeLvA9nbeGLu6i0hdJvbdFljjM6q5A5bcss3mYK5P8Aqwc4GOaAPtHwpBCfDsdjdXS6jciMG+MrB90kg3sGHYHdwvYYrx/x99r8K6vB4kgl8G2l9pMwuLm2smMFzJAwCvGwJ/eZXkcLgqCM13PwAubO5+GWlvbXElxesgk1CSVWEjXDgM24nqcEY9sVb+IFnpl9qVlpd7JoqzapFNAsN7ab5ZvlwfKkyNrAHvmgDt7eaO4gjmhYNFIodGHcEZBqSuL+DOoSal8MPD0s7Bp4rf7LKR/fiYxt+qV2lABRRRQAE4GT0rzXxGi/EHVrex0yytptLs082XUr+FpICXHCwxHAkfA++eFB4yTXR/EzU5NK8EanNbki5lRbWHAyfMlYRrj8Wz+FU/Cek3Hh+21S/wBbvViRCYLZDN+4tbSP5Y8DpuIG5ieSTjtigDO8XeJ1ayu9MsZftnlxbZptKvY1vbd15LLAcFsYztBOeRg18wQ/Eq+1L4hT3OlFHF9YvY6lNtKQvuIWS5ROqlkVDt/v59q9n+KHiCOPwtc6nceVqUccZeO4k0aa2yQeDDcjPluDgqSMHGO9eNfD/wAEPqUNt4hl1Ew3jv8AaI2nu4bGN5A27auTv2/McuFHOdvTNAHr5sYPEep6bZalpFpej7TuksZsGJJdgSOFiM58i3DM57O4XvXv1ukUdvGluEWFVAQJ90LjjHtivFdJ05RptrHObrT9Pv2Sx89ITDJKJDkwWkXLKhOWeV/mYDPPUesa1cweHfCl9cwKkNvp1m7ooHyosaHA+gwKAPJb+0f4qfGW5sbtnfwd4TKiaDcQl1fHnDY+8F9/T3rT+Ed9Y2nxO+I/h7S7iCWzS8j1FFixiOSVcTJx6Mo+mcVS+Eobwz+zzda+X36le211q88yjLNK4YqT64AWvIv2LbueT4ha+JGL+fYGSR25JbzV5z+JoA+x6KKKACiiigAooooAKKKKACiiigAooooA8h+KtrrV78TPCyeCLu2s/EsFldSyzXSboTa5QbGHU5fGMdOTSf8ACsfFPiaNbnxz481WK6zuS10FxawQ+2cEufc1rW6I37RN80nLp4ah8rJ6ZuZN2B+C5/Cvnz9oP4x+K7b4j6no3h7WJtO07TXEAFqQrSOFG4s2M9SRjpxQB63qUHjb4S3MV/a6je+LPBCY+2Q3hEl7Zr0LqwALKBzj68DrXsuj6lZ6xpdrqOmzpcWV1GJYpUOQykcGvmv9l74sa34o1y68K+LLo6kJLd5beeVQX4+8jH+IEHPPPFeh/DcD4feOtR8A3EjrpV7u1HQDIRgIeZoAfVT8wHoSaAPXaKKyfF11PYeFNZu7NttzBZTSxHGcMqEg/mKAOH8afFFNIuruPSbWO5srEvHf6jLNsiglAz5ScHfJjPBwufl3AnFeDab8VY73X9Rk8QeONfFskiQ20lhKtvuDMxaYR7CoAQICh/iJxS/EvTpLvwz4Ms9Gu7A2d9BFDNI98gdN8fnO8o2Bowx8xmyzg44wcVz/AIeh8FXFjd6at+lzZ24zJLJBIglYDO+OCIeY4H9+SRR7dqAPpbw5r3i3TVgE1ufF+jzkeXfWhihvLYkA7LiLIQkA8lTn1FXPEOuXtzLd+V4ltNL06G5+yM9nCJZY5MHCzPJkRZOADsPbnmvH/hb4qfTfDeu+GbO+0ix023lF1aT3+otZyiGblQrR78kNnucdDmvNvHPiPVrrx1faZfPHqDNaRwYF8s8NwVG5HmeLYku3JwXxtH3s4oA9Y8N+LtQ1bVLKHw14x1SPUp7YXLpqcsN5aKBF5r+aAqsiDhdynv7V6v4O8eXV7rsfh3xXpaaTrslv9ptmhnE1tfRj7zQuPTg7TyAa+N9N0uz8MaNca1HqQTVowrxFiyxzAnmNIlBLxtypeTYpB4B617xeaxd+JYvDWsLaXen3en69Yx2Nu+ntD5aTEiaNXZmEilOflwoAH4AH0dQSACScAUV4v4z1i9+KPiKfwT4PvJbfQ7Vv+J7rEHQYP/HtE2eWPRiOn55ALniT4wPdatJofw00aTxVq8ZImmjbZaW5B/ik6E/Qge9Y+o+KPjboFgNR1Lwt4f1G0hO+eGwdzPs6nA3Hp7A/Sum8cvY/CD4N6pL4RsoLU2cSpANud0jsE8xzj5m5zk9cYr5N+H3xe8Z2PjzTLu713UNQhnuljntrmctHIrtgjaeF65GBxQB9QfBe8k8deI9c+Il3am2inRdL02B2BeGGM5k3ehZz+lewV5p4QtIvDnxi8UaPZsVs9Ws4tbWAD5Ypd7RSkf7x2mvS6ACiiigAooooA+Pv2dPD92nxy8VavKhSz0Z7xJpMfKXZ2ULn1wGP0FfRPwTgWD4YaG6JsFykl1jOf9bI0n/s1ef69qC+BpfidogQRS6rGdV01hhDKZwIZVB7lZCD64ava9EsY9L0awsIV2x2sCQqPQKoH9KAON+IfgG28ZPNaajf20UF0gWMG1T7RC6fMGilyG6gEg54z0riNR+FuoW3hzVdK09U1C5ubaYOsV2LO3jZgQiCNVLOcYJLtzzzzXt11D5jwSLDDJLE+VaTqgPDFTjrgmmzSWdlKJJWhgkupFjDHCmV8YUZ7nA4+lAGJ8O/C9l4O8J2WjWBZvIXMzs+9nlIBYk/Xt2GKtzXSy+JPIM15EtpAZZI2tv3EoPQiQr95fQHvyK1be3htzKYI1QyuZHwPvMepP5CuM+KGvJ4U8EeKdcaa4WWO28qFJj+780rtTYPcsM/SgB3wXVB8MtEaNQqSJJIMDG7dK7bvxzn8a7avmH4GfGxtM8N6dpPjKweDTbaJIodWtkLxxL0UTgZ2E+v6DrX0xZ3Vve20dxZzxXFvINySRMGVh6gjrQBNRRRQBwfxhiludF0W2guJLZ7jWbSLzU5KZc8gHg4OD9RW74UjsZPB9pHobuLUxFI5LiMlywJBZw3JbcCTnqa4L9oLxRpdp4PktLS+hm8RxXMNzYWcH76ZpYpFf7q5IAAbJNdv4J1t/E+n2+vWd1BLot/axSW8QQiSKTnzAx784GOxBoA5q/8L2XimXUNIvZfElxuRorrUzcNBETjBjRMhWU5OcIR75rk/DngOHwToSnxNqsGjWtrIbYz2kyRPeIpyk7OVaRnI2r5YIAwSBzXt91d29p5IuZVjM0gijDH77noo9+D+VNnsLS4uobm4toZbiAERSOgZkz1wT0zigDlPDN94R17WIb/AEzWINU1KCHy4kkuN0kKgYZhEcFWPdsAn6Vh/F/xdBF4J8U2A03XGQ2U1uLyKxZofMKlcZ64yeWxt9667xR4Q0zX4xK0QtNUjYSW2pWyhbiCQdGVscj1U8EcGt6FHFuiTsJXCgO23AY45OPf0oA84+FH2Dxf8B9GsVdWt59L+wTbTkowTy2H1BGa8o/ZM8K6l4Z8f+OLLVIjFLYRx2rgg/MS7FWHsQufxFdzpbW3wq+LF7psjLaeE/EkMl/bbsLFa3US5lRfQFeceuAK6n4Oxz3+l6p4qvI2jn8R3ZvYkb7yWwASBT/wAbv+BGgD0CiiigAooooAKKKKACiiigAooooAKKKKAPNfEcy6V8dfCt1cAiDVNMudOjfHAlVllAz7gN+VeHftF/BDX7jxbe+JvClnJqVpqDiSe2h5lilPDEL/ABKTzxyMntX0F8W9D/tfR9JuYbqG0v8ATNUtbu2nlcIoYSBWXPfKsRjucVLq3xB0/wAO6/caf4sifSLbh7TUZctbXC45G8DCODn5Wx2IJoA8R/Zd+EXiLw34pn8SeJ7RtOEULwW9u7AyOzYyxA6AD8817d8U/CNx4p0e0m0e4Wz8Q6VcC9025YfKsq9Ub/ZYcH8PSopviXo92hj8KR3PiW9I+SLTU3Rg9t8pwiD6n8K3PDEPiD/SLrxLc2nmTbfKsrRP3dsoHILn5nY9zwOOBQBhfD/4h2niSZ9I1WBtG8VWwIutKuDh+Orxn+ND2IrtL2aC3s7ia8ZFto42eVn+6EAySfbGa8x+OFz4Yhi0yHV9HvtV8RTOTpUOmBku94IyVlXlFGRnJxz0NYttpfxaS+XxTqNzp88UcDr/AMIsLl1TYR0aTBDyY7tkZ70AcJb+H9c+JOnXXhjwfFHbeAYLw3FlrV/bskyLhj5UQzl0BZgCQPlODXJ+Hvg/4q8Ma19lu/B1zq0vn/Pf288LR+QBnEQkwocnu+cDoua9O0T9pWzmhje68I6hb2MRWOaa3nSQREnAULgZPH3Rziu/0v43/DzUYo3TxJbW+/OBdI8J46/eAFADvCXhDUWg1XWtdSDT/EOowpbxLaKkv2G3jz5aDcNrPySxxgk4HAFeVfFH4Ka14hs7LxFoAkfXApS9s7uOC3kuFDHa37v93vHv14J5Feyf8LY8A7d3/CXaNjOP+PlazdZ+OHw70qNWk8S2tyWBwlorTk/98ggfjigDyj4ffBnWNV01Y/E2kwaVD5xnkF3Ity823PlxBVPCZwzsW3P0GBX0DaW2i+DvDEEVw1jp2m2K7tzN5cMZ5JK7idoyTgZ4zivIvEXx+ubnybPwR4U1S7v7htkbX0flgf7XlqSxHQ5O0VgfByG/+IXxQ1qf4kXy6jfaCIpbPTldDbRs2cuEUlSVwo6nBPPNAHsXiuz1nxtpVlb+HtVTTPD99Hvu7xUdbt4yfuRAgbNw/iPODwK2dL8H6LpPhL/hG9Ltfsml+WY9sLlX56vvHO/PO7rmt0yRrKsRdBIwJVM8kDqQKfQB5hp00Wqw6r8NvH8onu3g2W1xIwVtStT92Vf+mqkfMB3APevM/DX7M9j4b8TjWtf8RRzaHp8n2pIzH5bEIdw81icADHOOvtX0B4q8KaJ4rtYrfX9Pju0hYvExJSSJj3R1IZT7giuUg+DvhZWjW6bV7+0jORZ3mpTSwH0BQthgPQ5FAGd8M5v+Er+JPifxtbRv/Yr28WlabOwIFyiMWkkUH+HfgA98V6vXlPwcabw74k8V+A52za6VMt7pmTki1nJYIPZGyPxr1agAooooAKKKKAPEv2g9Ptdai1GOZS93oujHVrUgHMLiZcuMdcqjDB49q9k0u6S+0y0u423JPCkqn1DKCD+tcdPbxXfxevba5RZIJvDiRyIwyGU3EgIP4Va+GVjqWh6FLoGqo7JpUpgs7o9Li26xn/eUfKR6rnvQB2Fc58QNLu9U8NSjSwralaSxXtqrHAeWJw4Un0bBX8a6Oud8XeJY9FijtbNFvNdu/ksrFT80jHjc2Puxr1ZjwAPXFAGHpnxc8F3WjLfXmu2WmyqSk9neSrHcQSA4ZGj+9kHjgYrwj42+PR8U5YdE8KMf+EasbhXu72ZWC3cv8EcaD53PXCgbj14AzXHa98I/HGofFDU7TV9NGp6pfK94t3CSlmWZuWZzjAHPy9c46iul0nQNU8MaxHous6Vd6HdLBNNDNZzrKTaoo3xWbdBPKx+eQ4IXoAKAMzUtEuL3w/daZNN9ms7TCyhpAsNqTwBJglEbPSGMPKe7A1o+HvCGpaFcW9h4R1bxHp13GpnnQziKSSPHEs0R/d2sXceYWcj+Guz0Gw1i+sjL4M0GK8voIWh0+8klWLTNJYjkQA5aeUfxTYOW74rI8T6R4z8OeHYLXVfC0K6DH++v57W7N2Ly6Yj/AEi8AAkeNfmYoBgnAzjigDn9S8b/ABIjSFNE8bNqszljvS0jSFkXALI7qCyjndIQqccE1WdvGfiiOO3v/GeuXlxdDd5Ni3lo8efm2INuU6/vX2IOxan399piQWYsRNrN1qlxiwtkg82S6VGKm+uYx94ZBEUHCKFBI610/iDR/GTWUFpoXw3vRpahri8S/vIpJdSuP4Gudr5dF6+VnGcDoMUAcrpWnaZoRe20e0GpX9wpj8uKZ3S4IPILja06qR8xXy4R3Zqn8J+IPG3gFL7UfDsmnXHh+aUzXFtMNtnFJ/EsMg2qWJyNkW7t161cE0Y1O60/VLK8t9QzCv8AZ2pRmCbWZn6y3DL8qWcXJ8pDjC80ur2et69LLc2ega/4itoYRHa3kdt5Nrck44iTI8m2A6CPDPxlgKAOu8B/ErUPHfxU8K23iTTrfTJbeK7nht45N2ZCihS2TkMBv4IGM19HV8S61ZQaPcrq1je3ek+INKmhlsY9WsGs9zIMyIXCmMD+FI1IBHJJNfU/ws+IWkfEPw9Hf6ZMou41Vby1P34JCOQfUdcHvQB2dFU9Z1G30fSLzUb1wltaxNNISQOFGe9Sabcteada3TRPC00SyGJ/vIWAO0+4zigDzX9oLTbe68PeH7+4t4p/7P1yzk2yAYZHkEbL06HeMj2r1FEWNFRFCoowqgYAHoK84+PwR/AUML7SZtVsI1Vj98/aY+PyBr0igAooooAKKKKACiiigAooooAKKKKACiiigDzv4m3DXHi74faKOY7rVWu5QFydsETOPw3bf0r0GeGK4iaOeNJY26q6gg/ga868Uhpvjn4HiMhWOGw1C4ChfvNiNOv0Y/lSeMPi5pGi6zN4e0e1utc8VrIIY9MtUIJYruyzn5VUA8ntQB3eoXum6Dpct3fT21hp9uu55HIjRB/KuFvtY1b4jeGrWX4d6mul6dcXEkF1qNzbOswiAHzW6nAOc4DH8ORWvq3grTvGD6JqPjCxaS7s4950/wC0F7VZSASWXgOQeATXXxRpFGkcSKkaAKqqMBQOwFAGF4L8LWfhPQ4NNtJrq7MZZ2ubyUyzSOxyzFj6nsOKwPjR490/wJ4Kv7q4uEGozRNFZ24fEkkjDAIHXAzkn2rU+IGga54h02O28PeJ5/D0gLGSSG3WRpRjgZPK4PcV8vS+F7/4ZeKp7zxwkepa3fYj0jWr2Tz7KHAJklkVvmMqjlUxyTxQBwOheB7k2Vvqvja/n0vTkTzYLSNQ95OvXcsZwEQ95HwOe9dFcLDdxW9vYaUIbeRT9nt3bz5Hj7kscMR6keXEMdW5rW1eSWHUrGKWC9udb1WUXcVqIBd3MKn7tzdoMeZM3BSI4SMEEit+x0y+tdb8zV/hv4om8NQL53kbFmn1C5HSW7OcsAekY+VfQ0AcS3hhtStlnWHTbLTg/wBnW82ec1y+P9VbKqgyt1yI1wD/ABmtHR/CtvYXskNjp8g1CBC9z5Zi+0wIB96WQ5hsl4Pd5fxrc07XxqVxq2peJ7i90a40+z83V5DH5F2kbMVisLFD/qo8AbnGGbPUCrvhm+bxLpUr+HfDUuqxwYk0/QLOPZpdq/aS7mfaLibuR8w4/EAFjSIrC004tcG1fSZjnzDLJb2E7Z4GcfaNQk9SMIe1UfEGra14d8Y2fiTw6Y49Vgt/IfT7mFIDc25IO020Y/0eNeoaVw3Srl+fFPgyxS98R+Hr+xv7tiNU8Vo8d9NBFg/u7aNOIRwAOy5zzUXwx8Pa349t5tV0fSbKz0BLhntI9YkeeKV84MsiKd1zL3LSHaDwooA6/wCDHjC58XfFvW7vxOlva6uulxRWFtbvvh8jeWkZHP3juK5I4+uK9+r5huvhV8TPD/i3TfFOn3mk67qNjLJNKwZoZrlTwYju+XbtyqqMKvp3r2vwb45XW799J1jSb7QvEEaeY1jdLvDJ/eSVfkcc9jkelAHZ0UUUAeZaoDYftDaHMkZC6poVxbO4xhjFIrj8t3616bXlfjwOfjp8NNgY4h1EnHp5cfX2r1SgAooooAKKKKAOF1iX7F8ZPDjZGNQ0q7tsYPWN4pBz+J6+9dnf2dvqFlPZ3sSzW06GOSNujKeCK4j4qH+zrzwl4hyVj03VUjnIzgQzgwsT7Ash/Cu+oA5P/hDLMzRCDWtfiSAY8iPU5NuOwYEk49Oa1dC8N6VobzS6fagXU/8ArrmRjJNL/vSMSxHtnA7VkeDZGfxR4zEzsZkv4lCsuNsf2ePbg9wfm/Wm6/4i8Safc3D2HhCa+0+2yzyrexrLKoHPlR8kn0BIzQB2FY/iTwzoviaCGDxBpltqEUL+ZGs6bgrYxkfhVTT/ABM+sR21zoWnS3lhPaG5Fy7+SN3O2LDDO/Iwem3v6UzwpBrF1f3useIrVbC5mVbe3sY7jzhDEuTlmGAXZiScDgBRQB0VvDFbQRw28aRQxqEREGFVR0AHYVIQCMHkVxdl4ul0rWYtD8WW9xBdXFx5FlqCQE215uJKDcuQkmOCrY5HBOa0fFXjPQ/DOIdRvYzqEg/cWER33Fwx4CpGOTk8Z6UAUPDfw38OeHPFmoeINKtDDeXa7RHkeVBk5fy1x8u4gE4rsq4h9c1Hwp4dttV8UQTT/arrfffZgZV05HHygKBlkXCqSB1JNLN8VPBUemTXsfiGxuFjH+ohfdO7HoixfeLHsMUAbHiLw7o/iDUNOfUURr2wczQ4YbtjAq6sP4o2BIIPBrdRFjRUjUKijCqowAPQV5c9jr40t/GFxp9w+svexXp0tGzLHZorKLdQODJtdnI7uSK7/wAPa7p3iLTVvtIukuLcsUbHDRuOqOp5Vh3B5FAFy+s7a/tZLa+t4bm3kGHimQOrD3B4ryW9+AXh2LxFFrHhjUNV8Nz78yx6bOUR17qO659jj2rv76/1bT/FtlC8H2rQ79fKDxId9pMoJy/qjAYz2YD1roqAPP4PAmq6pd2zeNvEbazY2cqy29jBai2id1OVabDMZCOoGQuecGvQKK53xH4w0zw3qNrb62Lm0trgALfvEfsyuSQEeQfdbjvge9AHM/FhzfeIfAWgxqrPd6yt4+WwRHbo0jEfjtr0ivMdHb/hI/jpq9+rb7Lw5p6afEccfaJyJHI9cIEH412viPxRoXhlIH8Q6tZaak5IiNzKIw5GM4z1xkfnQBs0VV0vULTVdPgvtNuYrqznXfFNE25HHqCOtTzypBBJLKSI41LsQCcADJ4FAD6Kr6dewajYwXlo5e3nQSRsUKEqenBAI/EVYoAKKKyb3xHpFjqsum3l9FBeRWT6jIj5AS3VtrSFsYABPrQBrUVmeHdd07xHpceo6NcG5spCQkvlsgb3AYA49+laTsqKzOwVVGSScACgBaKr6fe2uo2cN5p9zBd2ky7o54JBIjj1VhwR9KsUAFR3M8drbS3E7hIYkMjsf4VAyT+VNvDOtpObRY3uQjGJZCQpfHAJHQZxXCeA/CniSHWJPEPjjX5L3VZYzHHp9oxSytUPJAX+Nv8AaNAHA6x4/wBZ8S+O/CV14c0g6X4fmvxYxa7fWwMtyrjcyRIeVRtmN3fg8Yr0DXvhnpTmTUvC0VvoniZbs38WpRx7maU53LJnlo2BIK5xzkciqnx5/wBB8I6drqfKdC1W0vyQOkYkCP8Ahtc/lXo8MqTwxyxMHjdQysOhB5BoA8+OvfEizAjn8FaTqMmcGWz1kRJjjnEkefWt3w5F4ruL83viObTrO22kR6bZAykE95Jmxkj0VQPc1V1+4n0r4ieHrt5H/s7UIZdNkBY7Um4kiOOmTtdc/QVveItZi0HTWvri1vbmFWAcWcDTOo/vFV5wO5FAGnVDWdG03WooItWsbe8jgmW4iWZAwSRTlWGe4qJNZivdAXVdDT+1YZUEkKwOo80E9ixAB68HHTFc3431nWrqd/DXhvSNQF9doEfVZIttpaRsPmffn53A6KO+KAOn0jR9L0sSnS7K2tzK7PI8SAM7E8lj1Jz61o1wFnpdx8MvBmqHSg2q6bZubuG1mlEckUX3pR5jZDHO5hnHXGa3/CXi3T/FOhf2tp8V9Fabd4+1WrxMy4yGUEfMCO4zQBi/E34YaB8QY7NtWgVLy1lR0uUUbygbLRN6qwzx26iu0s7WCytY7azhjgt41CpHGoVVA6AAV5d4hk+IHiuey1Dwza2+jaXYTLdRW2psyT6kVyNjqv8AqoyDwG5zgkDGK9Fsb+8bQlvdT02W1vFiLy2cTidgR/CpHDZ7UAXbowrbSm52eQEJk3/d245z7YrB+H+g2Phzw5HY6NdfadKaWS4tMEFY4pGLhFI6qNxwfSta0vIr/SFu54JbaCWMs8V3H5bIvfep6cetYHw+1OG/0dF0XR5bHw/CgTT5ZHA89ASAyp1CHqCeoOcUAdZR3ry7X7P4heJvst7py23hi50tzLDbzT/aFvpOhWTZgCIrnHVs4OBiu28I6lqup6V5mv6O+kajGxjlh81ZUYj+NGXqp7ZwfWgDbooooA8x1Qrd/tFaFFukZrHQbifaPuqZJVTn0yB+gr06vJfhkza58XviH4gba9vbSQ6PbSLyCIwTIM/7xGa9aoAKKKKACiiigDI8X6Fb+JvDGpaLdllhvYWiLr1Q/wALD3BAP4VhfC/xFPq2kzaXrIEfiLRmFnfx7s7yB8sy+quBuB9cjtXReJLiG20W5NxdPaLKBAs0Yy6NIQilR65YYqCy8M6RZahaX9vYxR31rbfZEnUbWMXB2tj73Izznkn1oA1lijWR5FRQ743MBgtjpk96fXFXHjGPw54lvdP8YXUFjYzt52mX82I4ZEx80TMeA6nnnGQRjoa6K08QaNeW8NxaatYTwTOI4pIrhGV2PRQQeSfSgBdCt9OtIbq30nYIluZGlRGyElY73Hty2ce9aVcPpWqDw34hl07Xglqdbu57q0nLjyiwIAhJ/vlFD++SB0ruCQBkkAUAcdM41j4nJZyDfaaLZLdbD0+0TMyo2O+1EbHoWrq2tLZroXLW8JuQNolKDeB6Z61yGnadd2vxY1/VZSF0u40y0hDlsKJUeXIPvhl/Ou1oAKyNQ8OaTeyvcPY28d8Y2jS8jiVZ4sgjcj4ypGeDWvRQBwOi6fruv+E9DtNU1GaKJPMXUJ48xT3Yjcoi+qhwNzMME9BjOa7HSNJ0/R7X7NpVlb2cGdxSFAoJ9Tjqfc81dqpfajZ2BgW9uYoWnkEUSu2DI56Ko7n6UARW+rW9xrd5pcQka4tIo5Zm2/Iu/dtXPrhc49CK0K4Pw5qkFh8SfFOkai6w3l40F7ZmQhftEPlKhCeuxlII68iup1/XtM0DTbm/1a8ht7e3jMjlmAOB2A7k9AO5oA0Ipo5t/lSK+xijbTnaw6g+9YXxBvbPTvA2vXeprE9pFZStIkuNr/IcKc+pwPxrz3wJ481WTQEt7Xwj4hu9curie5eO5tTZwQh5WZd8z/LjaV+6CT6V12meF7/VrtNT8czW15MnzW+lwAm0tT6ndzK/+0wAHYDrQBh/s2aRZaZ8JNGns5VuJtQU3dzODktKxwVJPPygBf8AgNHxd8F6n4u8V+B3sWuoLGxuLl7y8tZYklt1aMBSocHOSMcK34daj+DJ/svxL8QPDMOfsOm6qLi2AGFjW4QSFB7A5/OvVKAPB/HHhLxvZzeJbHw1aXusWWp6Nb2dtePqMULwTRFtxZTt+Zgc5UAfTtUPgbxn/wALBvNSi0+eW2lE2bi+u42MYMBRBA6ShwN2MI6bRnqcZr6DooA+ebr4a+J9W0qOLV7O8kltvBSWluo1LaBqyPIyg7ZAGYZX5myvvXJeLP7Ws/E503VjcX3im5fR47SSLUQ0tqirH58RhDbuW3kuAVOSS2a+s6KAPPPi3oOqa1J4eks7CXV9JtLmR9R0mK6W3a6UxMsZ3MyqQjkNtJGfwrzuP4beLptLlg1mBr+5bwTeaWJPtak/a2ufNggLFgTtUIu4/KdvJwa9g8d+LB4Ut9HZdPlv59U1GPTYYo5FT946uwJLcY+TH41w9p8T7vVfF3he2ih/s23eXWLXVrSZkbbNaIhAEvTaCxO7gc89KAOJ8dfDfxdLoOh6boGiSf6DokMcM9vfRiWG83FpFZpJRtXJJBjB7DIUADqrrwVrN74u1eTxDoVzrSag8QtNTTVBClhD5QV4zGHDDB3E7Fbfu5Iqew+O2nvaazNqWjXNv9gsY7+L7PMJ1uUklEKhWwoyXZRkZXrzxW5qXxE1jTbqz0278ITrrl2s00Vot/EyGCJFZ5PMx1y20LjqDzjmgDzbSfh34msvBnhiwuPDN3PBYC7jv9LXVY0+0TvGgiulbzNu0YI2kgryQpzXXeGPAOvSeLtAm8YS3d7Z6f4dtoZJo9QdEe/juGfDKrgyYUjlgVbHOTUXi34xS3Hha5n8F6dPNdf2Cdae5mdEWyRsqmVOfMbcrZUccdTVpfjNDBrFppJ0i8vnjFpFfXUJHySTRq25YwMsq7huORjsDigDM+AmnapL4m8QTajqEt7pnh2SbQNNkMjMJgJnkd3yeXAaNM+gI9Sfca848C/FGHxZ4svNFTTGsHtxKdtzcqtyNj7fmgIDAHrkFh64r0egChr+lW2uaJf6VfLutb2B4JR/ssCD/OuF+DGtXEdhdeDtfl/4qDw832Zt/DXFt/yxmX1BXAJ9RzXpJ4rz/wAMRW/jXxAfFk1lbpZ2Uj2+j3CqVuJVUsskjMDzGzZCoeMDd3oA7q6tbe7RFuoY5lR1lUOoba6nKsM9wRkGpq4C6uPH3h6XcLWx8V6dkk+SRZ3ijP8AdP7t/wA1pI/inpkE5ttc0jxDo94OkNxp0kgf/ceMMrenBoA6Hwz4cTw/f609pLixv7kXUdqBhYHKgSbfZmG7HqTW/XmniHxxqthLo2uvourWvhZJ5Ib8SwfvwjKPLmMQy4jDZz0PIOK6yw8aeGL+CGa08Q6TLHKAUxdoCc+xOc+1AEfxA0ObxH4bbSoSvlz3EH2hWOA0Kyq0i/ioI/GuiVQihUAVQMAAYAFcdr+v6npvjvw5bqi/8I1fxSxzXKxGTFzx5Slh9wEbuTwemeldkSAMk4FABRRWff61pmn3ltaXt/awXdy4jggeUCSVj0Cr1NAD9c06PWNHvNOnkljhuomhdom2sFYYOD24qeytobKzgtbWMR28EaxRoOiqowB+Qrn/AAvrl1resa9IsezRLSVbW1laMqZpEB85wT1QNhQcdVPNQT/ErwTA5WXxXogYPsYC8jJU+jYPHTvQB1tFea3XjLXNf1nTJ/h7Y/2loUDsdQuLhfIjuFIwqwO4yxBySQNvbNdzrtldapoV3aWl7Npl3PEVjuYcF4H7EZ4ODQBo1xfxe8aReBfBF5qeUa+kxb2UTEDzJm4X8B94+wqPR4fiDIILbV7rw/BHCVEt5bxySS3AB5IjOFjJHXlsEnFR/F3wRpHivwnrL6jbh7xLCQW87EkwFfnBUdASVGSBkjigDR+F3hdfCHgnTtLMnnXW0z3c3/PWd/mdvzP5AV1dcb8G9WuNc+FvhnUL1t1zLZIJG/vFflz+O3NdlQAUUUUAFFFFAHIfE2V4NK0idSgij1iyMxc4UIZQCT+JH44rrJ5VggklfO1FLHHoBmsH4h6ZJrHgfW7GBQ1xLauYQRn94o3J/wCPAU/wxqsfirwVYajbuMX9oCTj7rlcMCPUNkY9qANC3ez1vS7a4aBJ7W4RZkWaMHgjIyD35qhp/hDw5p1+L2w0LTLa7DFhLFbIrBj1IIHX3ql8Lb59Q+H2iTSqEmSDyJFHZ4yY2/VTU0uqXU/j+HSLeVEtLawN3dLjLOzvsjGewG2Qn8KANXXNG03XtPex1qxt76zcgmKeMOuR0PPQ+9cpbfC7w/b3cUgk1aS0ibcthNqM0ltnqCUZjnB6A8e1d1UdxPFbQPNcSpFCgyzyMFVR6knpQBU1XR9P1bTruw1G0hntLtdk8bLxIMcZ9xgYPbArjbPwp4w0WzgtND8YxT2kHyxR6rYec4j7KZFdWbHAyecDnNbC+LJNSZh4Y0ufVIhwbpmEFuf9125f6qCPemTHx1JGGgXw1bvkko5nmGM8DcNvbvj8KAMuRPihJJ5Ky+EIIxt/0nZcSFvUeXkY/wC+qn07wZq11e2974v8T3mpPA4kjs7NBZ2oYHILKpLPgjPzNj2qaZfiGZmMMvhNYs/KHjuCwHuQw/lWvpd1r6G4XWtPsiscZeOWxuGfzCP4djqCpP1I96ADxHoEmsS20tvrOqaXNAGXdZSKA4bGQysrKcY4OMio9B8I6Vo1x9rSOW81I/evr2QzTt/wJvuj2XA9qTR/F+malfrp7i6sdTYEi0vYGhkbHXbkbWxn+EmuhoAyPEfhvR/Etqlvrun297GjbozIvzRt/eRhyp9wQaydO+HHhDT7yK7g0Cye8iYOlxOpmlDA5B3uSc/jUnjHW73R9a8LRWbQPDqN/wDY54HU72Uxs29Gzxt2EkHqDXU0AV9QvbfTrOW7vJBHbxDLuQTjnHarFcd8R47rUE0TRLWG5aDUb9BdyxL8sdvHmR9zdt20L/wKrnxI8SReEvBGraxIfnghIhTOC8rfKij3LEUAc58IiL/WfHutxH/R73W2hix0IgjSIsD7lTXpFcn8KfD0nhf4faLpdzzeRw+Zck8kzOS8hJ7/ADMa6ygAooooAKKKKAOS+IvguHxtbaJb3N5JbQ6fqcWouIwwaYIjqYwysrITv+8DkY6U60+HnhW0j02ODSIgmnJcx26tI7AC4AE2/LHzC4AyXya6uigDidO+Ffg3T4rmKDRt8dzZjT5UuLqadTbhtwjAkdsAEAjGCMcYok+FvhCWzS3l0yeRUkaVZXv7hplLIEYCUyb9pVQCu7aQOldtRQBx2tfDLwhrKWyX2jrst7P+z41t55YB9n7RERsu5R1AOcHkVLc/DvwvcalHftpzx3apFGzwXc0QlWMAIJAjgSYAAG8HgV1lFAHM6D4E8O6Dqx1PTLB0vfLaJJJrmWfykY5KxiRmCAkdFArpqKKAOX+KN/Npnw91+5tWK3AtHSNh/Cz/ACg/gWzWzoOnRaRolhp1sipDawJCoXphVA/pWB8W7KTUPhn4kt4VLSGykdVH8RUbsfjtxW/oF9Dqeh6dfWrK8FzbxyoynIIZQR/OgC6kiSbvLdW2nadpzg+h96dXEeD2OleN/FWhSOxjmkTV7UP1KzfLIAe4Ein6bqt/FW+bT/AepzK7Ju8qEsG27VeVEJz24Y0AdZWNN4W8PzOzzaFpTux3MzWkZJPqeK2EAVVVfugYFLQBFa28NpbxW9rEkMEShEjRQqqo6AAdBVXXdHsde0qfTdVgFxZTgCSPcVzg56ggjkVjeJfGljo16um2tvdavrTgMun2Cb5AD/E5JCxr7sR+NUf7d8byruh8F2kQx9241hQ2f+ARsMfjQBmx/CHSIXC22u+K4LRQQtrHq8ojUegzzgfWui8K+BvD/hhmm0yxVr5+ZL65YzXMh9WlbLfhnFc+uufEy3bM/g3RbtCcbbfWPLZfcl48GkbXfidOzNB4M0S1Rf4LjWPMZvcFUwKAPR6zv7C0nfO/9l2G+ckyt9nTMh/2uOfxrlNH8f3C6ha6d4x8O33h28uW2QzO6z2sj/3RMvAYnoGAzXeE4GT0oARVCKFQBVAwABgAUtcdofiO+8TeJ3bRVjXwtZhkkvXTJvZuRthP/PNcHL9zwOMmuxoAKyvFk8dr4W1ieYKYorOZ2DdCAhJzitQsoZVJAZugz1rzn4+ahLB4Ak0iz51DX7iLSLcZ5zKcM34KGNAFn4CQvB8HPCaSgKxslcAHPDEsP0Irvqp6Np8WlaRY6dbj9zaQJAn+6qhR/KrlABRRRQAUUUUAFcH4IVvD3i7xB4Zk2JazSHV9NA4zHK375AP9mTn6SCu8rgPjLFNZeHIvFGnKf7T8PTLex4baZYsgTRE+jITx6gUAWPhm32OfxRojk79P1aV0XGAIZ8TJj2+dh+FVtZvo/DfxWtL/AFIGPTdasE09LsnCRXEcjuqOe28SEAnuMd6zobjxGdd/4SzQfDV1i+hW01HSb+aOCUmPJjnjfLKQNzKQSM8V0fgXVL/xDFqs+srbKqXPkJZxL5iW5QZKmU8Stk8lflBGBnBNAGtr2qahYvHFpmh3WpyOMhkljijTn+JmbI9eFNYum+FrrVLoan42livbkNug06Mk2loOwCkDzH9XYfQCtXxPr/8AZRt7OygN5rN4Straqevq7kfdjXu34DJIrXjdobNXvJIw6RgyuPlXIHzHnoOtAC3E0FnbPNcSRwW8SlndyFVFHcnsKyPDmvSa8809tp88OlAYgurj5GuD/eWMjIT0Y4z2GOawtLiPjx4tW1FB/wAI0rb7CycZF0QeLiUd14yif8CPOMdzQBymp+KNSXUZ9N0jwxqlzdo21Z7gLBaEf3/Nycj2ALe3epvCviY6g50zW44NP8SQDM9iJdwYc4kiJwXjOOuOOhwRXS1j+I/DWkeI7dItYso5zGcxSglJYj6o64ZT9CKAL1/p9pqAhF7bxT+TIJYi65KOOjA9jUOrtqUVvNJpUdvcT7AscE7GNN2eWZwCcAdgO1cbcx3/AIDvbG9utfv9Q8Nyy/ZrldRZGNmG/wBXJ5m0MRuwpLE8MD2r0FGV0V0YMjDIIOQRQByGi+FLt/Ea+IfFF+l/qkUZitIIEKW1mrfeKKSSXPQueccAAV2BIAJJwBQenHWvJ/inbfELUPCWsC1m0uxso4XeSKxaSS7uYxyyK7BQhZc8gE9qAN3wFfT+JPE3iHxEtw7aOrjTdOQMdjrET5kwHQ7nJAPolc/8QoG8afFXw14URi+l6QBrWqrj5SQcQRk+pO449K7Cy8QeH9G+GkOu6aYk8O2mnieEQ8ARqvCj37fWsL4G6beHw1c+JtbVhrPiWc6jMH6xREYhiHHRUxj6mgD0iiiigAooooAKKKKACiiigAooooAKKKKACiiigBGUMpVgCpGCCMg15v4QnXwN4kl8H6jKY9LvZWuNBlkb5dpwXtcn+JWJKjup9q9JrH8WeHbDxTok2l6ojmGQh0kjbZJDIpysiMOVZTgg0AYPjxUsPEvhDXD8nk3xsJpAOfLnQqAf9nzBHW74z0GHxR4V1TRLlzHHfQND5i9UJHDD6HB/CuX0yC/8R+F/EHhTXboS6pp7i0N9sC+dlVkhnK9jyuccZU4rqLLVLhvEE2kXUCborSO4E8b5DEkqwK4+XkHHJyPSgDl/AnjQLHB4c8Yumn+KrYi3aOQFVvQOFmhJ4ZWHOAcg5Brf8R2HiHUbpYNL1a103TXQCWVLcvdA558tidgyOMlTitXV7yy0ywm1DUnjit7dd7SOM7fTHvnAAHU1agkE0Mcqqyh1DAOu0jPqD0NAGd4d0HT/AA9YC00yHYpO6SV2LyTP3eRzyzH1NZOo+M7b+0JdL8P28mtavE/lyw25xFbn/ptL91MenLe1U/HGtX8+s2PhLw7J5GqahE89xedfsVqCFaRR3ckhVzxnntiuk8O6LY+HtGttL0qHyrW3XaoJyzHuzHuxPJPcmgCtra+IZNEhfRZNOg1dSrvHcq8kD8fMm4YYezYPTpWDHZfES7Xz59X8P6bIRxaw2Ulyq8d5GdSefQCu5ooA5jwB4ik8TaLcNqFtHb6nYXcthfQKdyJNGeSpPVSCrD6+1dDeW0V5aT2tygkgnRo5EPG5SMEfka8+1zSr3wb4suvFuhQS3elX4H9tafGxL7lAC3MK92A4Zf4h05FejIwdFZfusMjjFAHKeKNK1yz0y2k8EXcFq+nxbY9MlhU29yoxiPP3kOBgMDj1FZVr8XvCX2KN9UvZdLvgMT2NzbSCaBx1VlCnv0I4PY16DTHhjfdvRW3DacjqPSgDlfC0lz4g1STxDd2s1pZLH5OmwXCFJdh5eZlP3S2AAOu0c4ziuRtJk8efG1bu2Im0PwfFJCJQcpJfyjDAeuxO/qap/EO+8UfDP4a64NMmjvrCLbHp95JIfPskkcKEZcEOE3YVs56ZBxXoPw48M2nhHwbp2lWJZwieZNM/LzSt8zux7kk/yFAHTUUUUAFFFFABRRRQAVxfxluha/DLXiSN80It4wccvI6oo592FdpXDfEGJNX8Q+EfD8iCSGe9bULgHkeXbLuAI7gyNHQB0XiG2v5fCmo22kuI9Tezkjt3zjbLsIU57c45qTwvYppvhzTLOO3NssNtGnlE5KHaMgnuc5ye5rTqC/vLfT7Ke8vZkgtYEMksrnCooGSSaAK1jpFnZahe30UbNeXbAyzSMWbA6KCeijso45NYPxNS6vtAi0TT45mn1idLN3QHEUJO6ZmPYeWrD3LAVT07VfEni6SO40uE6B4fJV47q5jD3V4nXKRniJSO75bB6Cu6oAjtoY7a3iggRY4YlCIi9FUDAA/CpKKKACiiigCK6t4bu3lt7qKOaCVSjxyKGV1PUEHqK5vRPDg8JG6fSbq9k0ZYWZNJP70ROOcQsTlQeRsJIyRjFdTRQBn6BrNlr+kwajpcwltphwcYKkcFWHUMDkEHoRWhXDeJ7KfwtfzeKdEWRrUnfq+nxjKzR950XtKo5OPvAEHnBrtLW4iu7WG5tpFkgmQSRuvRlIyCPwoA8b+K/h7T7FdF8L6RGba08V63ELy2Vz5QRMySlE6LuwoYDg+le0IixoqIoVFGAAMAD0ry74+l9P0nw14jVWaLQtat7q42/wAMLZjc/QbxXp8MqTwxywurxSKGRlOQwPIINAD6KKKACiiigAoor5m8N63r03xouIL5/tWsTatfWqQyG483S7ZYiIZljDiEwkP3XLHndnGAD6Zor5Y8I6nr2uaF8L4z4pebW/7Vu4JZriIzS2biGTMcoZsu2ORuIxuXggc+teCr7WPHnwdv49RvAuszLeWAvLYGA+YjvGkgAPynhTxQB6bRXxpJ488YTeGE8RxXGo+Rd2I8IJGZGB+2CGNjPjPDlzIN3Xiup8Qyy6P8Z7LQ9S8QKlnZ6fp8QF7q91b+a4wrMgiz5jtjJD4BzyaAPqKivmzwBqrXPx91631HWYiYtauo7e0n1S5WXaEbAjgAMTLn+8RjnHQVm/A3xHql34t8Pw+MtR1BdMkF4NFZrhjFd3InYOJjn5nVcBFPA4xyeQD6looooAKKKq6pf22l6bdX99IIrW2iaaVz2VRk0AcrbN5HxivoocFbrRYpZwOqukzqhP1DMP8AgNatlYX1t411O8I36be2kIDbhmOWMsCuOuCrA59qzfh3pdz5d74k1iPy9Z1srNJGf+XeBQfJh+qqct6sTXY0AZmsaJZ6xPp8l+JJFspxcRxbyI2kA+Uuv8WCcjPQ4NaLusaM8jBUUZZmOAB61i+JPEKaQ9vaW1tLf6tdEi3s4Thm9Xc9EQd2P4ZPFYieCp9d3T+O73+0y5+XTrdmisohnIG0HMh9S+c+goAq/DJTrWt+JfGDj91qVwLOwYdGtIMqrj2Zy7e4xXoNMhijghSKBFjiRQqIgwFA6ADsKfQAUUUUAFYGu6brLXq6h4f1NIpwnlvZ3il7aUdj8pDI3uM57g1v0UAclp3iDUrfxdBoXiGKyilvLV7m1e1LlWKMA6bmAycMG6DjNdbWD4z8Op4i0tY45mtdStn+0WN4n3recA7WHqOcEdCCRR4L1uXXNFEl5B9m1K2ka1vYP+ec6fex6qchgfRhQBm/F3w5P4s+G+u6NZY+13EG6AE4BkRg6j8SoH41b+HHiGHxR4K0rVIQyO8QjmjYYaOZPlkQj1DAiulry3wbGfB/xY8QeHGYR6Vrg/tnTUPQS9LiNffOHx6H60AepUUUUAFFFFABRRRQAVzVlpk9z46vtZvIykVtbLY2QbuGIeVx9TsX/gBrpaKACuX8SaFP4l1a1tNQCr4dtiJ5oCcm9lByit/0zUjcQfvHHYc9RRQAUUUUAFFFFABRRRQAUUUUAIyhlKsAykYIIyDXJfD6KbShqvh2ZHEOl3H+hyFSFa2ky8YB7lTuT/gIrrqKAK+oWdtqNjcWV9Ck9rcRtFLE4yrqRgg/hXmHwfnn8K65rHw61OSR/wCzibzSJXJPm2LtwuT3Rsr/APqr1esq60CwufEljrskb/2jZwS28TqxA2SFSwI78qMenNAGrRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVi+KNEOvw2dnPKo05bhZrqIjJnVPmWP/d3BSfUDHetqigAooooApWel2trf3d7HHm7uiPNlY5YqOig9lHOB7mrtFFABRRRQAUUUUAFFFFABVe2sre2uLqeCMJLcuHlI/iYKFB/IAfhViigArzv4sxNDq3gLU4FYz2+vwwbgOkcyOj5PYHgflXolNdFkADqrAEEZGcEdDQA6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kawamoto, HK Jr, Pravin-Kumar, KP, Atypical facial clefts. In: Pediatric Plastic Surgery, Bentz, M (Ed), Appleton Lange, Stamford, CT 1998. p.184, Copyright &copy; 1998 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19377=[""].join("\n");
var outline_f18_59_19377=null;
var title_f18_59_19378="Topical corticosteroids";
var content_f18_59_19378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62402%7EPC%2F76586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62402%7EPC%2F76586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of representative topical corticosteroid preparations (classified according to the USA system)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Potency group*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Corticosteroid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vehicle type/form",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade names",
"        <br/>",
"        (US)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available strength(s), percent",
"        <br/>",
"        (except as noted)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available in US",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"18\">",
"        <strong>",
"         Super high potency",
"         <br/>",
"         (group one)",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Betamethasone dipropionate, augmented",
"       </td>",
"       <td>",
"        Ointment, optimized",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Clobetasol propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, emollient base",
"       </td>",
"       <td>",
"        Temovate E&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam aerosol",
"       </td>",
"       <td>",
"        Olux-E&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam aerosol (scalp)",
"       </td>",
"       <td>",
"        Olux&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shampoo",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution (scalp)",
"       </td>",
"       <td>",
"        Temovate&reg;, Cormax&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spray aerosol",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Halobetasol propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Ultravate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Ultravate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Vanos&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Tape (roll)",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        4 mcg/cm",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Ointment (petrolatum)",
"       </td>",
"       <td>",
"        Psorcon&reg;, ApexiCon&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        <strong>",
"         High potency",
"         <br/>",
"         (group two)",
"        </strong>",
"       </td>",
"       <td>",
"        Amcinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cyclocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, augmented formulation (AF)",
"       </td>",
"       <td>",
"        Diprolene&reg; AF",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Halcinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Halog&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Halog&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream anhydrous",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Ointment, emollient",
"       </td>",
"       <td>",
"        ApexiCon&reg;, Florone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, emollient",
"       </td>",
"       <td>",
"        ApexiCon&reg; E",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Desoximetasone",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"14\">",
"        <strong>",
"         High potency",
"         <br/>",
"         (group three)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Amcinonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cyclocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Cream, hydrophilic emollient",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Luxiq&reg;",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Cream aqueous emollient",
"       </td>",
"       <td>",
"        Lidex-E&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mometasone furoate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desoximetasone",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Topicort LP&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Florone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog &reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Triderm&reg;, Aristocort HP&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Aristocort A&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"10\">",
"        <strong>",
"         Medium potency",
"         <br/>",
"         (group four)",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol spray",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"       </td>",
"       <td>",
"        0.2 mg per 2 second spray",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Mometasone furoate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Elocon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone valerate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Westcort&reg;",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clocortolone pivalate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cloderm&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         Lower-mid potency",
"         <br/>",
"         (group five)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Prednicarbate",
"       </td>",
"       <td>",
"        Cream, emollient",
"       </td>",
"       <td>",
"        Dermatop&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Dermatop&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Desonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        DesOwen&reg;, Tridesilon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Desonate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Beta-Val&reg;, Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone valerate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Westcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Hydrocortisone butyrate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Locoid&reg;, Locoid Lipocream&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion, spray",
"       </td>",
"       <td>",
"        Cortizone10&reg; maximum",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone probutate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Pandel&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"13\">",
"        <strong>",
"         Low potency",
"         <br/>",
"         (group six)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Alclometasone dipropionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Aclovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Aclovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Aristocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Desonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        DesOwen&reg; , Tridesilon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        DesOwen&reg;, LoKara&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Verdeso&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Beta-Val&reg;, Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shampoo",
"       </td>",
"       <td>",
"        Capex&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil (scalp)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Derma-Smoothe/FS&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil (body)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Derma-Smoothe/FS&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        <strong>",
"         Least potent",
"         <br/>",
"         (group seven)",
"        </strong>",
"       </td>",
"       <td rowspan=\"4\">",
"        Hydrocortisone (base)",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Hytone&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Hytone&reg;, Nutracort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Hytone&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Texacort&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Hydrocortisone acetate with pramoxine 1 percent combination",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Pramosone&reg;",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Pramosone&reg;, Analpram HC",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Pramosone&reg;, Analpram HC",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol foam",
"       </td>",
"       <td>",
"        Epifoam&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Hydrocortisone (base)",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cortaid&reg;, Hytone&reg;, Nutracort&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cortaid&reg;, Hytone&reg;, Synacort",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Aquinil HC&reg;, Sarnol HC&reg;, Cortizone-10&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spray",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Cortaid&reg;, Noble&reg;, Scalp relief&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Listed by potency according to the USA classification system: group one is the most potent, group seven is the least potent. Other countries use a different classification system with only four or five groups.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Vehicle and base ingredient(s) for generic products, in some cases, may not be identical to trade version.",
"      <br>",
"       &Delta; Inactive US trade name for specific product; brand may be available outside US.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved; and Tadicherla S, Ross K, Shenefelt D, Topical corticosteroids in dermatology; Journal of Drugs in Dermatology 2009; 12:1093.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of topical medication for adult use",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        BID/1 week",
"       </td>",
"       <td class=\"subtitle1\">",
"        TID/2 week",
"       </td>",
"       <td class=\"subtitle1\">",
"        BID/4 week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Face and neck",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trunk",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"       <td>",
"        180 g",
"       </td>",
"       <td>",
"        240 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One arm",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One leg",
"       </td>",
"       <td>",
"        30 g",
"       </td>",
"       <td>",
"        90 g",
"       </td>",
"       <td>",
"        120 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hands and feet",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body",
"       </td>",
"       <td>",
"        180 g",
"       </td>",
"       <td>",
"        0.75 to 1 kg",
"       </td>",
"       <td>",
"        1.25 to 2 kg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For children use one-third to one-half these amounts.",
"    <div class=\"footnotes\">",
"     BID: two times per day; TID: three times per day.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldstein BG, Goldstein AO, Practical Dermatology 2nd ed, Mosby-Year Book, Inc, St. Louis, MO, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19378=[""].join("\n");
var outline_f18_59_19378=null;
var title_f18_59_19379="Patient information: Breast cancer screening (The Basics)";
var content_f18_59_19379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16169\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?36/43/37563\">",
"         How to do a breast self-exam",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/10/44193\">",
"         Patient information: Breast biopsy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6115\">",
"         Patient information: Common breast problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/59/6066\">",
"         Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/56/6018\">",
"         Patient information: Common breast problems (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/6/44134\">",
"         Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breast cancer screening (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/breast-cancer-screening-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7715233\">",
"      <span class=\"h1\">",
"       What is breast cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breast cancer screening is a way in which doctors check the breasts for early signs of cancer in women who have no symptoms of breast cancer. The main test used to screen for breast cancer is a special kind of X-ray called a mammogram. This is usually combined with regular breast exams done by the doctor or nurse.",
"     </p>",
"     <p>",
"      The goal of breast cancer screening is to find cancer early, before it has a chance to grow, spread, or cause problems. Studies show that being screened for breast cancer lowers the chance that a woman will die of the disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715240\">",
"      <span class=\"h1\">",
"       Who should be screened for breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Experts recommend screening for most women age 50 to 70, and for some older women who are healthy. (Screening should involve mammograms, as well as breast exams done by a doctor or nurse.) Some women age 40 to 49 should also be screened. For instance, women who are at high risk of breast cancer sometimes need to begin screening at a young age. This might include women who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Carry genes that increase their risk of breast cancer, such as the &ldquo;BRCA&rdquo; genes",
"       </li>",
"       <li>",
"        Have close relatives who got breast cancer at a young age",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should talk with your doctor or nurse to decide when you should start screening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715247\">",
"      <span class=\"h1\">",
"       What are the benefits of being screened for breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main benefit of screening is that it helps doctors find cancer early, when it is easier to treat. This lowers the chances of dying of breast cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715254\">",
"      <span class=\"h1\">",
"       What are the drawbacks to being screened for breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The drawbacks include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        False positives &mdash; Mammograms sometimes give &ldquo;false positives,&rdquo; meaning they suggest a woman might have cancer when she does not. This can lead to unneeded worry and to more tests&mdash;including a biopsy in some cases, which can be painful. False positive results are more likely to happen in women younger than 50 than they are in older women.",
"       </li>",
"       <li>",
"        Radiation exposure &mdash; Like all X-rays, mammograms expose you to some radiation. But studies show that the number of lives saved by catching cancer early greatly outweighs the very small risks that come from radiation exposure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715261\">",
"      <span class=\"h1\">",
"       What happens during a mammogram?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before the mammogram, you will need to undress from the waist up and put on a hospital gown. Then your breasts will be X-rayed 1 at a time. Each breast is X-rayed twice. Each is X-rayed once from the top down and once from side-to-side so that the radiologist can get a good look at all the tissue. To make the breast tissue easier to see, a nurse or technician will flatten each breast between 2 panels. This can be uncomfortable, but it lasts only a few seconds. If possible, avoid scheduling your mammogram just before or during your period. Breasts are extra sensitive at that time. Also, do not use underarm deodorant or powder on the day of your appointment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715268\">",
"      <span class=\"h1\">",
"       What happens after a mammogram?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a radiologist (the doctor who will look at your X-ray) is able to look at your mammogram right away, you might get the results the same day. If not, you should get a phone call or letter with your results within 30 days. If you do not hear back about your results, call your doctor or nurse's office. Do not assume that your mammogram was normal if you hear nothing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715275\">",
"      <span class=\"h1\">",
"       What if my mammogram is abnormal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your mammogram is abnormal, don't panic. Nine out of 10 women with an abnormal mammogram turn out NOT to have breast cancer. You will need more tests to find out what's really going on.",
"     </p>",
"     <p>",
"      If your doctor thinks your abnormal result is probably NOT due to cancer, he or she might suggest that you wait and have another mammogram in 6 months. If your doctor thinks the abnormal result might be due to cancer, he or she will probably send you for more tests. Other tests could include a more detailed mammogram, called a diagnostic mammogram, or an ultrasound of the breast.",
"     </p>",
"     <p>",
"      If the other tests still show any suspicious findings, your doctor or nurse will probably order a biopsy. During a biopsy, a doctor takes samples of breast tissue and sends them to the lab to be checked for cancer. Biopsies are usually done by taking some tissue from the breast with a needle during a mammogram or ultrasound. But in some cases biopsies involve a small surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715282\">",
"      <span class=\"h1\">",
"       What about breast exams?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse should do a breast exam on a regular basis as part of breast cancer screening. During the exam, the doctor or nurse will look at your breasts and then carefully feel both breasts and the area under both arms. He or she will look for lumps, nipple changes, or any changes in the tissue or skin that could signal cancer.",
"     </p>",
"     <p>",
"      Some women also like to do exams on their own breasts. No study has shown that breast self-exams lower the risk of dying from breast cancer, and most experts do not encourage self exams. Still, if you decide to do breast self-exams, make sure you know how to do them the right way (",
"      <a class=\"graphic graphic_table graphicRef53792 \" href=\"UTD.htm?36/43/37563\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715289\">",
"      <span class=\"h1\">",
"       Can I have a breast MRI instead of a mammogram?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women are hearing a lot about breast MRIs in the news. But breast MRIs are not for everyone. Compared with mammograms, breast MRIs give more \"false positives\" and sometimes lead to unneeded biopsies. Still, breast MRIs are sometimes used to help find breast cancer in young women who have a high risk of breast cancer. Doctors do not recommend breast MRI to screen for breast cancer in women who do not have a high risk of breast cancer. In any case, MRIs don&rsquo;t replace mammograms. They are used with mammograms for the high-risk women who need them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715296\">",
"      <span class=\"h1\">",
"       How often should I have a mammogram?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who choose to start breast cancer screening at age 40 are usually screened once a year until age 50. After age 50, most experts recommend that screening be done every 1 to 2 years, depending on the woman's risk of breast cancer.",
"     </p>",
"     <p>",
"      Routine screening (with mammograms and breast exams) should continue as long as the woman is otherwise healthy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7715453\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       Patient information: Common breast problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=see_link\">",
"       Patient information: Breast biopsy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=see_link\">",
"       Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"       Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       Patient information: Common breast problems (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/59/19379?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16169 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19379=[""].join("\n");
var outline_f18_59_19379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715233\">",
"      What is breast cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715240\">",
"      Who should be screened for breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715247\">",
"      What are the benefits of being screened for breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715254\">",
"      What are the drawbacks to being screened for breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715261\">",
"      What happens during a mammogram?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715268\">",
"      What happens after a mammogram?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715275\">",
"      What if my mammogram is abnormal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715282\">",
"      What about breast exams?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715289\">",
"      Can I have a breast MRI instead of a mammogram?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715296\">",
"      How often should I have a mammogram?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7715453\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/43/37563\">",
"      How to do a breast self-exam",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=related_link\">",
"      Patient information: Breast biopsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=related_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=related_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_59_19380="Lactulose: Patient drug information";
var content_f18_59_19380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lactulose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     see \"Lactulose: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"     see \"Lactulose: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Constulose;",
"     </li>",
"     <li>",
"      Enulose;",
"     </li>",
"     <li>",
"      Generlac;",
"     </li>",
"     <li>",
"      Kristalose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acilac;",
"     </li>",
"     <li>",
"      Apo-Lactulose&reg;;",
"     </li>",
"     <li>",
"      Laxilose;",
"     </li>",
"     <li>",
"      PMS-Lactulose",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat changes in thinking caused by very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation). It may take 1 to 2 days to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702353",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lactulose or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-galactose or lactose-free diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking other laxatives.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with juice, milk, water, or sweet foods to make it taste better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Mix the liquid with water first. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug for hard stools (constipation), drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10786 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-48A44A7773-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19380=[""].join("\n");
var outline_f18_59_19380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186542\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014359\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014358\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014363\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014364\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014366\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014361\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014362\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014367\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014368\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=related_link\">",
"      Lactulose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=related_link\">",
"      Lactulose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_59_19381="Echocardiogram apical 4-chamber TV carcinoid heart disease";
var content_f18_59_19381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68261/4chtrcar_conv.mp4?title=Echocardiogram+apical+4-chamber+TV+carcinoid+heart+disease\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical 4-chamber showing tricuspid valve pathology in carcinoid heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram in a patient with carcinoid syndrome shows thickening and immobility of the tricuspid leaflets which remain open in systole as a result of severe fibrosis. The right atrium and ventricle are dilated due to the tricuspid regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19381=[""].join("\n");
var outline_f18_59_19381=null;
var title_f18_59_19382="Brinzolamide and timolol: Drug information";
var content_f18_59_19382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brinzolamide and timolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/46/34532?source=see_link\">",
"    see \"Brinzolamide and timolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9496865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Azarga&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9508323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9508542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Reduction of intraocular pressure:",
"     </b>",
"     Ophthalmic: Instill 1 drop in affected eye(s) twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9508543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9508641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Azarga&trade;: Brinzolamide hydrochloride 1% and timolol maleate 0.5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9508544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If using additional topical ophthalmic preparations, separate administration by at least 5 minutes. Remove contact lens prior to administration and wait 15 minutes before reinserting. Shake bottle well prior to administration. Gently close eyelid after instillation. Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions. If changing from another ophthalmic antiglaucoma agent, discontinue use of first agent and initiate brinzolamide/timolol the following day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9508364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9508494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Taste perversion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (6%), eye irritation (4%), eye pain (3%), foreign body sensation in eyes (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal eye sensation, anterior chamber flare, asthenopia, blepharitis, blepharitis allergic, conjunctival hyperemia, conjunctivitis allergic, COPD, corneal disorder, corneal erosion, cough, eye discharge, eye pruritus, eyelid erythema, eyelid margin crusting, eyelid pruritus, hypotension, insomnia, lacrimation increased, lichen planus, ocular hyperemia, pharyngolaryngeal pain, photophobia, punctuate keratitis, rhinorrhea, scleral hyperemia, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9508369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brinzolamide, timolol, other beta-blockers, sulfonamides, or any component of the formulation; current or history of bronchial asthma; severe chronic obstructive pulmonary disease (COPD); severe allergic rhinitis and bronchial hyper-reactivity; sinus bradycardia, second-/third degree atrioventricular (AV) block, overt cardiac failure, cardiogenic shock; hyperchloremic acidosis; severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9508370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Patients with compromised corneas (eg, patients with diabetes or low endothelial cell counts) or contact lens wearers may have an increased risk for corneal edema; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Systemic absorption and adverse effects (similar to sulfonamides) including blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, and fulminant hepatic necrosis may occur with ophthalmic use. Bradycardia and/or hypotension may also occur due to beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition; control heart failure prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment as use has not been evaluated in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease or other myasthenic symptoms (diplopia, ptosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narrow-angle glaucoma: Use has not been evaluated in narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment as use has not been evaluated in this population; use is contraindicated with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: In general, patients with mild-to-moderate COPD or bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring; use is contraindicated in patients with asthma or severe COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral carbonic anhydrase inhibitors: Concurrent use with oral or other carbonic anhydrase inhibitors is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Formulation contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Based on systemic absorption, may impair mental alertness and/or physical coordination. Use caution when performing potentially dangerous tasks such as driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension. Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia. Patients undergoing major surgery should be gradually tapered off therapy prior to procedure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9517862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9508365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women with the combination product. Use only if benefit outweighs risk. Bradycardia and arrhythmia have been reported in an infant following ophthalmic administration of timolol during pregnancy. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9508367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9508368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol is excreted in breast milk following oral and ophthalmic administration, though clinical beta blockade is not likely at recommended ophthalmologic doses. It is unknown whether brinzolamide is excreted in breast milk. Use of the combination product during lactation is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9508546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic exams and IOP periodically; heart rate/signs of cardiac failure (patients with severe cardiac disease)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azarga (AR, AU, BE, CH, CN, CZ, DE, DK, EE, FR, GB, GR, HK, IE, IL, IT, MY, NL, NZ, PE, PH, PL, PT, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Azorga (BR);",
"     </li>",
"     <li>",
"      Elazop (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9508538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide inhibits carbonic anhydrase, leading to decreased aqueous humor secretion. This results in a reduction of intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timolol: Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9508539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kaback M, Scoper SV, Arzeno G, et al, &ldquo;Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5%,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2008, 115(10):1728-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/59/19382/abstract-text/18538406/pubmed\" id=\"18538406\" target=\"_blank\">",
"        18538406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/59/19382/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Odeh M, Oliven A, and Bassan H, &ldquo;Timolol Eyedrop-Induced Fatal Bronchospasm in an Asthmatic Patient,&rdquo;",
"      <i>",
"       J Fam Pract",
"      </i>",
"      , 1991, 32(1):97-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/59/19382/abstract-text/1985142/pubmed\" id=\"1985142\" target=\"_blank\">",
"        1985142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9364 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19382=[""].join("\n");
var outline_f18_59_19382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496865\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508323\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508542\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508543\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508641\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217340\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508544\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508364\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508494\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508369\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508370\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298884\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9517862\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508365\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508367\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508368\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508546\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390242\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508538\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508539\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9364\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9364|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/46/34532?source=related_link\">",
"      Brinzolamide and timolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_59_19383="Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections";
var content_f18_59_19383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Diane E Pappas, MD, JD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19383/contributors\">",
"     J Owen Hendley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19383/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/59/19383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus has long been known as an etiologic agent of colds, which are frequent but otherwise relatively minor and self-limited illnesses. Rhinovirus can also infect the lower respiratory tract and trigger asthma exacerbations in both adults and children, highlighting the fact that this viral pathogen causes greater morbidity than previously recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is devoted to the epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections. More general discussions related to the \"common cold\" are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/55/24440?source=see_link\">",
"     \"The common cold in adults: Diagnosis and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=see_link\">",
"     \"The common cold in adults: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus is the etiologic agent of most common colds and is responsible for one-third to one-half of cases in adults annually [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. More than 100 serotypes have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The average adult experiences two to three colds per year, while children average 8 to 12 colds per year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/4\">",
"     4",
"    </a>",
"    ]. Children are the major reservoir for rhinovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus is a member of the picornavirus family [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ]. It is a small (30 nanometer) single-stranded RNA virus, about the size of a ribosome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. The capsid has icosahedral symmetry and contains 60 copies each of the four rhinoviral polypeptides (eg, VP1 through VP4) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ]. The full genomes of 99 human rhinoviruses have been fully sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/8\">",
"     8",
"    </a>",
"    ]. On comparing these sequences, there are highly conserved motifs that may serve as potential targets for antiviral drug development [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most notable is the viral surface, which contains numerous canyons that surround the attachment site for host-cell receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ]. Over 90 percent of rhinoviruses use this site to attach to the intercellular adhesion molecule-1 (ICAM-1) receptor expressed on the surface of host cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ]. Antibody neutralization occurs when IgG binds to the viral surface, which obstructs access of the host-cell receptor to the viral attachment site at the base of the canyon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus&nbsp;is present in&nbsp;nasal secretions&nbsp;for five to seven days, but may persist as long as two to three weeks in the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/10\">",
"     10",
"    </a>",
"    ]. Infection occurs when virus is deposited on the nasal mucosa after inoculation into the nose or onto the conjunctival surface [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/4\">",
"     4",
"    </a>",
"    ]. This most often occurs via self-inoculation, although small-particle aerosol and large-particle aerosol transmission are also possible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study, using a mask placed closely over the nose and mouth, demonstrated that rhinovirus was present by PCR analysis on the mask after coughing, talking, and breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/11\">",
"     11",
"    </a>",
"    ], but it is unclear whether this is a result of aerosolization or close contact with the mask. In another study using married couples,&nbsp;the conditions required for transmission were present only on the second or third day&nbsp;after inoculation, as this is the time of greatest viral shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus,&nbsp;the period of maximum contagiousness is most likely within the first five days of illness. Oral inoculation is an ineffective route of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virus must attach to receptors on host cells to establish conditions necessary for intracellular release of viral RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/13\">",
"     13",
"    </a>",
"    ]. The nasopharynx is the initial site of infection, regardless of the route of inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. The viral recovery rate in the nasopharynx remains higher than that of the nasal epithelium for 10 days following viral inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/10\">",
"     10",
"    </a>",
"    ]. Infection may spread anteriorly to the nasal mucosa covering the turbinates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early apoptosis of infected cells, regulated by interferon, minimizes rhinoviral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/14\">",
"     14",
"    </a>",
"    ] and allows extrusion of infected cells from the mucosa. The virus is cleared from the upper airway between two and three weeks after infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little histopathologic destruction of the nasal epithelium following rhinoviral infection. Studies using electron microscopy, scanning microscopy, and in situ hybridization all suggest focal findings with minimal changes in the surrounding tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, microscopic examination of the nasal epithelium demonstrated well-preserved epithelium without obvious abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/15\">",
"       15",
"      </a>",
"      ]. Although neutrophils in the lamina propria and extracellular erythrocytes significantly increase within two days of inoculation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/15,16\">",
"       15,16",
"      </a>",
"      ], the number of mast cells remained unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of volunteers who were inoculated with rhinovirus show localization of virus and few infected nasal epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study demonstrated that only one to two percent of the cells that sloughed into nasal secretions during rhinoviral infection contained rhinoviral antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Entry into nasal epithelial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intercellular adhesion molecule-1 (ICAM-1) is the host receptor for attachment of most rhinoviruses. It is a glycoprotein immunoglobulin with five domains, two of which fit in a lock-and-key arrangement to the attachment site at the canyon base of the rhinoviral surface [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/20\">",
"     20",
"    </a>",
"    ]. ICAM-1 may exist in either a membrane bound form (mICAM-1) or a soluble form (sICAM-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICAM-1 is usually expressed on non-ciliated epithelial cells of the adenoid and nasopharyngeal mucosa (18); in addition, ICAM-1 is present on endothelial cells, in the germinal center, and on the basal surface of the ciliated epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/21\">",
"     21",
"    </a>",
"    ]. ICAM-1 is not normally present on the luminal surface of nasal epithelium, as demonstrated in studies utilizing immunohistochemical techniques in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro study of bronchial epithelial cells infected with rhinovirus has shown that ICAM-1 expression is upregulated following rhinovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. In vivo studies of the nasal epithelium have shown a similar increase in ICAM-1 expression within 24 hours after rhinoviral inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/22\">",
"     22",
"    </a>",
"    ] with return to baseline by day nine.",
"   </p>",
"   <p>",
"    The soluble form of ICAM-1 (sICAM-1) has been shown to have antiviral properties [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/20\">",
"     20",
"    </a>",
"    ] and has an mRNA distinct from that of mICAM-1. In bronchial cell cultures, sICAM-1 is down-regulated during rhinovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/20\">",
"     20",
"    </a>",
"    ]. Down-regulation of sICAM-1 combined with up-regulation of mICAM-1 promotes rhinoviral infection of respiratory epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Role of cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once rhinovirus attaches to the ICAM-1 receptor, it is taken into the cell. Entry of virus triggers a sequence of events outlined in the figure (",
"    <a class=\"graphic graphic_figure graphicRef64931 \" href=\"UTD.htm?8/26/8622\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In response to infection with rhinovirus, epithelial cells in culture and in vivo, release interleukin-8, a chemoattractant (IL-8) for polymorphonuclear cells (PMNs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/3\">",
"     3",
"    </a>",
"    ]. IL-8 is locally produced and rapidly increases in nasal secretions following rhinovirus challenge. Nasal challenge with IL-8 results in a significant influx of PMN's within hours and in increased nasal resistance within 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/23\">",
"     23",
"    </a>",
"    ], suggesting that IL-8 must also act directly at the cellular level.",
"   </p>",
"   <p>",
"    It is postulated that oxidative stress resulting from rhinoviral infection activates cellular mechanisms that lead to the production and release of IL-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/24\">",
"     24",
"    </a>",
"    ]. IL-8 has been shown to cause up-regulation of adhesion molecule receptors on neutrophils and can cause neutrophil degranulation in addition to chemotaxis of eosinophils, T lymphocytes, and basophils [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, cytokine elaboration, especially IL-8, plays an important role in the influx of PMN's into nasal secretions and development of symptoms in rhinoviral infection.",
"   </p>",
"   <p>",
"    Local production is further supported by the in vivo observation that IL-8 mRNA was significantly increased in nasal epithelium of symptomatic children during viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/25\">",
"     25",
"    </a>",
"    ]. Studies of volunteers inoculated with rhinovirus also demonstrated that symptoms during infection correlated with an increase in the concentration of IL-8 in nasal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Role of kinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kinins are produced on-site in nasal mucosa and submucosa of rhinovirus-infected volunteers. The following observations have been made regarding the role of kinins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When applied to the nasal mucosa, bradykinin has been shown to cause symptoms that mimic the common cold, including rhinitis, nasal obstruction, and sore throat [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/2,27\">",
"       2,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analysis of nasal secretions in adults with symptomatic experimentally-induced rhinovirus infection demonstrates significant increases in the concentrations of bradykinin and lysylbradykinin, both of which are vasoactive peptides [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/2,16\">",
"       2,16",
"      </a>",
"      ]. In addition, increasing symptom scores correlate with increasing kinin concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asymptomatic infections do not result in increased kinin concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Kinins released in the nose following plasma exudation may augment symptomatology of the rhinoviral infection and may cause an increase in vascular permeability, vasodilatation, and glandular secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Entry into airway epithelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinoviruses may be associated with acute exacerbations of asthma, although it is unclear if this effect is mediated through direct infection of the lower respiratory tract or through indirect mechanisms.",
"   </p>",
"   <p>",
"    Lower respiratory tract infection was investigated in vitro by exposing human bronchial epithelial cells to rhinoviruses and in vivo after experimental infection of human study participants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/28\">",
"     28",
"    </a>",
"    ]. In situ hybridization demonstrated the presence of rhinovirus in bronchial biopsy specimens from 5 of 10 volunteers who were inoculated with rhinovirus type 16 by intranasal aerosol insufflation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/28\">",
"     28",
"    </a>",
"    ]. Hybridization signal was localized to the epithelium, with occasional detection in the basal and subepithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, rhinovirus may infect the lower respiratory tract during the course of a typical rhinoviral cold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VIRAL REPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus remains detectable by culture in the nasopharynx for two weeks following inoculation during experimental rhinovirus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/10\">",
"     10",
"    </a>",
"    ]. Viral detection is terminated between two and three weeks, coincident with appearance of serum neutralizing antibody. In contrast, symptoms usually diminish by five to seven days, before virus has cleared.",
"   </p>",
"   <p>",
"    A plausible explanation for the discrepancy between early symptom abatement and later viral clearance is that the inflammatory response induced by infection of nasal epithelial cells is successful in reducing the elaboration of pro-inflammatory signals by infected epithelial cells in the nose. Infected cells undergo apoptosis and are extruded from the nasal mucosa, limiting spread of virus to neighboring cells. The extruded cells are swept posteriorly by the combination of plasma exudation and increased glandular secretion. Symptoms diminish as the number of infected epithelial cells in the nasal mucosa declines. Apoptotic infected cells may then be swallowed after transport to the nasopharynx .",
"   </p>",
"   <p>",
"    It is important to further evaluate this hypothesis since it may have a direct bearing on effective therapies for rhinovirus infections. If this hypothesis is correct, effective dampening of the inflammatory response in the nose may result in increased viral replication in the nasal mucosa and, perhaps, prolongation of symptomatic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus infection may be asymptomatic or symptomatic with the usual signs and symptoms of the common cold.",
"   </p>",
"   <p>",
"    In adults, nasal discharge, nasal obstruction, cough, and",
"    <span class=\"nowrap\">",
"     sore/scratchy",
"    </span>",
"    throat are characteristic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/29\">",
"     29",
"    </a>",
"    ]. Symptoms typically resolve in five to seven days; fever is not usually associated with adult illness.",
"   </p>",
"   <p>",
"    Children may initially have fever; they also have cough and nasal discharge and obstruction more frequently than adults. The duration of symptoms is longer, with 70 percent of children still reporting symptoms by day 10 as compared with only about 20 percent of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ASTHMA EXACERBATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinovirus may cause increased severity and duration of respiratory symptoms, including decreased lung function, in asthmatic children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that as many as 50 percent of asthma exacerbations are associated with viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/14\">",
"     14",
"    </a>",
"    ]; more than half of the asthma exacerbations in children are specifically associated with rhinovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ]. Not surprisingly, hospital asthma admissions and asthma related mortality correspond to the rhinoviral peak in the early fall as children return to school [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both allergen exposure and elevated IgE levels predispose patients with asthma to more severe respiratory symptoms in response to rhinoviral infection. This may be a result of impaired antiviral immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ]. Atopic patients infected with rhinovirus who are then exposed to ragweed experienced increased bronchial reactivity as compared to infected atopic patients without ragweed exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, in young adults with mild asthma and elevated IgE, rhinoviral infection produced persistent upper respiratory tract symptoms and increased lower respiratory tract symptoms, including cough and wheeze, as compared to asthmatic individuals with low IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Necrosis of lower respiratory tract cells is the major predictor for the severity of asthma exacerbations in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"     1",
"    </a>",
"    ]. Infection with rhinovirus induces apoptosis in bronchial epithelial cells from normal subjects in culture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/33\">",
"     33",
"    </a>",
"    ]. Rhinoviral replication and cell necrosis is greatly increased in primary bronchial epithelial cells from asthmatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early apoptosis is significantly reduced in the cells of asthmatic individuals infected with rhinovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. This leads to cell lysis, which releases and perpetuates infection, leading to increased viral replication (up to eight times greater than in non-asthmatic subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/14\">",
"     14",
"    </a>",
"    ]. Early apoptosis is regulated by Type 1 interferon; elaboration of interferon-beta is markedly deficient in primary bronchial epithelial cells from asthmatic subjects when the cells are infected with rhinovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of cells from asthmatics with interferon-beta restored apoptosis to rhinovirus infected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19383/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. These studies suggest that abnormalities in the cellular response to viral infection that result in impaired apoptosis and increased viral replication may be responsible for the severe and prolonged symptoms typical of asthmatic individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       \"Patient information: Cough, runny nose, and the common cold (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=see_link\">",
"       \"Patient information: The common cold in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhinovirus is one of the most common etiologic agents of the common cold and may play a role in asthma exacerbations. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children are the major reservoir for rhinovirus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rhinovirus, a member of the picornavirus family, attaches to the intercellular adhesion molecule-1 (ICAM-1) receptor expressed on the surface of host cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection occurs when virus is deposited on the nasal mucosa after inoculation into the nose or onto the conjunctival surface. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little histopathologic destruction of the nasal epithelium following rhinoviral infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local production of various cytokines and kinins result in a cascade of cellular events leading to classic symptoms of the common cold. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of infection usually abate before virus has cleared. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Viral replication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms in adults and children are similar, although children may have associated fever and a longer duration of illness. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rhinovirus may play an important role in asthma exacerbations in children and in atopic individuals. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Asthma exacerbations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/1\">",
"      Heymann PW, Platts-Mills TA, Johnston SL. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. Pediatr Infect Dis J 2005; 24:S217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/2\">",
"      Proud D, Naclerio RM, Gwaltney JM, Hendley JO. Kinins are generated in nasal secretions during natural rhinovirus colds. J Infect Dis 1990; 161:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/3\">",
"      Hendley JO. The host response, not the virus, causes the symptoms of the common cold. Clin Infect Dis 1998; 26:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/4\">",
"      Winther B, Gwaltney JM Jr, Mygind N, Hendley JO. Viral-induced rhinitis. Am J Rhinol 1998; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/5\">",
"      Peltola V, Waris M, Osterback R, et al. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis 2008; 197:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/6\">",
"      Hendley JO. Clinical virology of rhinoviruses. Adv Virus Res 1999; 54:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/7\">",
"      Hendley JO. Rhinovirus colds: immunology and pathogenesis. Eur J Respir Dis Suppl 1983; 128 (Pt 1):340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/8\">",
"      Palmenberg AC, Spiro D, Kuzmickas R, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009; 324:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/9\">",
"      Poland GA, Barry MA. Common cold, uncommon variation. N Engl J Med 2009; 360:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/10\">",
"      Winther B, Gwaltney JM Jr, Mygind N, et al. Sites of rhinovirus recovery after point inoculation of the upper airway. JAMA 1986; 256:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/11\">",
"      Huynh KN, Oliver BG, Stelzer S, et al. A new method for sampling and detection of exhaled respiratory virus aerosols. Clin Infect Dis 2008; 46:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/12\">",
"      D'Alessio DJ, Peterson JA, Dick CR, Dick EC. Transmission of experimental rhinovirus colds in volunteer married couples. J Infect Dis 1976; 133:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/13\">",
"      Subauste MC, Jacoby DB, Richards SM, Proud D. Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest 1995; 96:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/14\">",
"      Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/15\">",
"      Winther B, Brofeldt S, Christensen B, Mygind N. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol 1984; 97:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/16\">",
"      Naclerio RM, Proud D, Lichtenstein LM, et al. Kinins are generated during experimental rhinovirus colds. J Infect Dis 1988; 157:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/17\">",
"      Arruda E, Boyle TR, Winther B, et al. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis 1995; 171:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/18\">",
"      Bardin PG, Johnston SL, Sanderson G, et al. Detection of rhinovirus infection of the nasal mucosa by oligonucleotide in situ hybridization. Am J Respir Cell Mol Biol 1994; 10:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/19\">",
"      Turner RB, Hendley JO, Gwaltney JM Jr. Shedding of infected ciliated epithelial cells in rhinovirus colds. J Infect Dis 1982; 145:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/20\">",
"      Whiteman SC, Bianco A, Knight RA, Spiteri MA. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem 2003; 278:11954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/21\">",
"      Winther B, Greve JM, Gwaltney JM Jr, et al. Surface expression of intercellular adhesion molecule 1 on epithelial cells in the human adenoid. J Infect Dis 1997; 176:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/22\">",
"      Winther B, Arruda E, Witek TJ, et al. Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection. Arch Otolaryngol Head Neck Surg 2002; 128:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/23\">",
"      Douglass JA, Dhami D, Gurr CE, et al. Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. Am J Respir Crit Care Med 1994; 150:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/24\">",
"      Zhu Z, Tang W, Gwaltney JM Jr, et al. Rhinovirus stimulation of interleukin-8 in vivo and in vitro: role of NF-kappaB. Am J Physiol 1997; 273:L814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/25\">",
"      Noah TL, Henderson FW, Wortman IA, et al. Nasal cytokine production in viral acute upper respiratory infection of childhood. J Infect Dis 1995; 171:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/26\">",
"      Turner RB, Weingand KW, Yeh CH, Leedy DW. Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds. Clin Infect Dis 1998; 26:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/27\">",
"      Proud D, Reynolds CJ, Lacapra S, et al. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 1988; 137:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/28\">",
"      Papadopoulos NG, Bates PJ, Bardin PG, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000; 181:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/29\">",
"      Gwaltney JM Jr, Hendley JO, Simon G, Jordan WS Jr. Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA 1967; 202:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/30\">",
"      Pappas DE, Hendley JO, Hayden FG, Winther B. Symptom profile of common colds in school-aged children. Pediatr Infect Dis J 2008; 27:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/31\">",
"      Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996; 154:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/32\">",
"      Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ 1997; 314:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19383/abstract/33\">",
"      Deszcz L, Gaudernak E, Kuechler E, Seipelt J. Apoptotic events induced by human rhinovirus infection. J Gen Virol 2005; 86:1379.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8335 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19383=[""].join("\n");
var outline_f18_59_19383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Entry into nasal epithelial cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Role of cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Role of kinins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Entry into airway epithelium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VIRAL REPLICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ASTHMA EXACERBATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8335|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/26/8622\" title=\"figure 1\">",
"      Rhinovirus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=related_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/55/24440?source=related_link\">",
"      The common cold in adults: Diagnosis and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_59_19384="Lentigines before laser therapy";
var content_f18_59_19384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75757%7EDERM%2F55782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75757%7EDERM%2F55782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Lentigines on the dorsal hands before laser treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Lentigines on the dorsal hands after laser treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lentigines on the dorsal hands resolved after a single treatment with a Q-switched alexandrite laser.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19384=[""].join("\n");
var outline_f18_59_19384=null;
var title_f18_59_19385="Evaluation and management of thrombocytopenia by primary care physicians";
var content_f18_59_19385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of thrombocytopenia by primary care physicians",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19385/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19385/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19385/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/59/19385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will provide an overview describing the most common medical disorders to be found in adults with newly recognized thrombocytopenia, who may present in a primary care setting. It will also provide a general guideline for outpatient management of the thrombocytopenic patient as concerns activity restrictions, safety of invasive procedures, and use of antiplatelet and anticoagulant agents.",
"   </p>",
"   <p>",
"    General approaches to thrombocytopenia in adults and to the patient presenting with a bleeding diathesis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11328209\">",
"    <span class=\"h1\">",
"     WHAT IS A LOW PLATELET COUNT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal platelet count in adults ranges from 150,000 to",
"    <span class=\"nowrap\">",
"     450,000/microL,",
"    </span>",
"    with mean values of 237,000 and",
"    <span class=\"nowrap\">",
"     266,000/microL",
"    </span>",
"    in males and females, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/1\">",
"     1",
"    </a>",
"    ]. Thrombocytopenia is defined as a platelet count less than",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    (150 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L),",
"    </span>",
"    keeping in mind that 2.5 percent of the normal population will have a platelet count lower than this. (See",
"    <a class=\"local\" href=\"#H11382687\">",
"     'Follow-up of minimal asymptomatic thrombocytopenia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Definitions and normal values'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OFFICE PRESENTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ISOLATED ASYMPTOMATIC THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common office or outpatient presentation of a patient with isolated thrombocytopenia is the",
"    <strong>",
"     unexpected",
"    </strong>",
"    discovery of a low platelet count during a routine evaluation (",
"    <a class=\"graphic graphic_table graphicRef50310 \" href=\"UTD.htm?29/60/30668\">",
"     table 1",
"    </a>",
"    ). The diagnostic evaluation of these patients, as described below, guides their appropriate management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory error",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of errors may contribute to a falsely low platelet count:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clotted specimen &mdash; The specimen may have been improperly drawn or underanticoagulated, leading to the presence of small clots within the blood sample and resultant thrombocytopenia.",
"     </li>",
"     <li>",
"      Wrong patient &mdash; The blood sample may have been mislabeled, and thrombocytopenia reflects a disorder in a patient other than the one in question.",
"     </li>",
"     <li>",
"      Other laboratory error &mdash; A number of technical errors leading to a falsely low platelet count are possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H23#H23\">",
"       \"Automated hematology instrumentation\", section on 'Platelet error flags'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Repeat testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A platelet count that does not make sense within the context of the clinical findings should be repeated before extensive evaluation is undertaken. Examination of the peripheral blood smear is an important part of the evaluation of a low platelet count and should not be neglected.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For symptomatic patients presenting with low platelet counts, such retesting should be performed immediately.",
"     </li>",
"     <li>",
"      For asymptomatic, non-bleeding patients with modest reductions in platelet count (eg, 75,000 to",
"      <span class=\"nowrap\">",
"       100,000/microL),",
"      </span>",
"      testing may be repeated in one to two weeks' time, provided the patient is advised to immediately report any changes in clinical status or bleeding during this interval.",
"     </li>",
"     <li>",
"      For those with minimal degrees of thrombocytopenia (eg, 100,000 to",
"      <span class=\"nowrap\">",
"       150,000/microL)",
"      </span>",
"      there is much less urgency; testing may be repeated in one or more months, as a small percent of these patients will develop a normal platelet count with observation only [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11382687\">",
"       'Follow-up of minimal asymptomatic thrombocytopenia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of all components of the complete blood count, including the white cell differential, and description of the peripheral blood smear, is of paramount importance in assuring that disorders such as myelodysplastic syndrome, congenital platelet disorders (eg, macrothrombocytopenia), acute leukemia, and microangiopathy (eg, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura) are not missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pseudothrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish true thrombocytopenia from pseudothrombocytopenia. The blood smear must have been examined to confirm the presence of a low platelet count, and to exclude the possibility that platelet clumping occurred in an EDTA-anticoagulated blood sample (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 1",
"    </a>",
"    ). Although the distinction between true thrombocytopenia and pseudothrombocytopenia should have been made by the laboratory technologist prior to the physician's receiving the report, this does not always happen. Even if the technologist has appropriately noted platelet clumping on the peripheral blood smear, the falsely low platelet count may still be recorded and cause confusion.",
"   </p>",
"   <p>",
"    Pseudothrombocytopenia caused by EDTA-dependent platelet agglutinins occurs in about 1 in 1000 normal adults. It has no clinical importance, requires no further investigation, and no follow-up other than making sure that subsequent platelet counts are obtained using an anticoagulant other than EDTA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Drug-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A drug-associated etiology must be excluded in all patients with isolated thrombocytopenia. Although drug-induced thrombocytopenia may be first encountered as an incidental observation in an asymptomatic patient, it more commonly presents with very low platelet counts and signs and symptoms of bleeding, such as petechiae and purpura, perhaps only because symptomatic patients are more commonly recognized.",
"   </p>",
"   <p>",
"    Medications taken intermittently or taken daily but begun only within the past month are more likely to be the cause of the thrombocytopenia than medications that have been taken regularly for many years. Drug-induced thrombocytopenia is typically caused by drug-dependent antibodies formed against a new antigen on the platelet surface created by drug binding to a platelet surface protein.",
"   </p>",
"   <p>",
"    In the evaluation of the patient with suspected drug-induced thrombocytopenia, it is critical to ask explicit questions. In response to the generic question, \"What medicines do you take?\", patients will typically describe only physician-prescribed medications. Patients commonly assume that their physician is not interested in non-prescription medications that they regulate themselves (eg, vitamins, nutritional supplements, herbal remedies, alternative medicines, and even common foods such as walnuts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/3\">",
"     3",
"    </a>",
"    ]) or, in some cases, medications that have been prescribed by other physicians. Explicit inquiries must be made regarding each of these categories. Also, it is not uncommon for patients to take medications prescribed for other family members. All of these potential exposures must be accounted for.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    is perhaps the most common cause of drug-induced thrombocytopenia and is commonly overlooked in the patient's history. Patients often do not tell their physicians about quinine, since they assume it is a harmless, natural product that they, rather than their physicians, regulate and that they take only occasionally for symptomatic leg cramps. Quinine in beverages, such as tonic water, can also cause thrombocytopenia. Quinine is also present, often listed as \"cinchona\" the natural product from which quinine is derived, in common preparations sold for leg cramps and other symptoms in many merchandise and nutrition stores (",
"    <a class=\"graphic graphic_table graphicRef60296 \" href=\"UTD.htm?21/20/21836\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A complete list of all case reports describing drug-induced thrombocytopenia, organized by generic drug names, is available at the following website:",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    . The listing on this website is current as of October 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Each article is evaluated to determine the level of evidence for the drug causing thrombocytopenia (eg, definite, probable, possible, and unlikely). This list can guide the physician regarding which drugs are the most likely causes of thrombocytopenia, and therefore should be discontinued first. Reports of thrombocytopenia associated with herbal remedies, supplements, and beverages are also assessed in this website. This website also provides a list of all drugs that have been associated with thrombocytopenia and drug-dependent, platelet-reactive antibodies detected by the BloodCenter of Wisconsin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H11#H11\">",
"     \"Drug-induced thrombocytopenia\", section on 'Evidence for particular drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for the diagnosis of drug-induced thrombocytopenia is provided by prompt recovery to a normal platelet count within approximately one week after stopping the drug. No treatment is necessary, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is often given because the diagnosis of immune thrombocytopenic purpura (ITP) is often considered in the differential diagnosis.",
"   </p>",
"   <p>",
"    Definite confirmation of a specific drug as the cause of thrombocytopenia requires readministration of the drug. This may not be appropriate in many patients, and may involve risk in patients with severe thrombocytopenia. However, when the offending drug is a commonly used agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , a food, or an herbal product), which the patient will likely encounter again in some form, it may be prudent to re-administer the drug under carefully supervised conditions rather than risking re-exposure at an unpredictable time. Such positive documentation of a common drug as the etiology of thrombocytopenia provides the support required for absolute avoidance. Support for the diagnosis of drug-induced thrombocytopenia can also be provided by the demonstration of drug-dependent, platelet-reactive antibodies. These assays require specific expertise not usually available in local laboratories, but are available at the",
"    <a class=\"external\" href=\"file://www.bcw.edu/\">",
"     BloodCenter",
"    </a>",
"    of Wisconsin.",
"   </p>",
"   <p>",
"    Drug-induced thrombocytopenia is described in more detail elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gestational thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pregnant woman, mild asymptomatic thrombocytopenia discovered near term is nearly always caused by the condition termed gestational thrombocytopenia, present in about 5 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/6\">",
"     6",
"    </a>",
"    ]. The etiology of this disorder is unknown. It is clinically unimportant, unless the platelet count is below",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    and there is concern regarding the safety of epidural anesthesia. By definition, this disorder does not cause severe or symptomatic thrombocytopenia, resolves spontaneously following delivery, and is not associated with thrombocytopenia in the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia may be the initial disease manifestation in as many as 10 percent of patients infected by the human immunodeficiency virus (HIV). An appropriate history looking for HIV-related risk factors as well as consideration of HIV testing is essential in the assessment of any patient with newly diagnosed thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other viral agents commonly associated with thrombocytopenia include hepatitis C virus (HCV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella zoster virus (VZV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Inciting events'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H15#H15\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Hematologic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary immune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary immune thrombocytopenia (ITP, idiopathic thrombocytopenic purpura) is the \"default\" diagnosis for a patient with isolated thrombocytopenia, in whom other etiologies have been excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. If the remainder of the complete blood count and examination of the blood smear are normal, ITP is the probable diagnosis, provided that a drug-associated etiology, HIV infection, gestational thrombocytopenia, and myelodysplasia have been excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with incidentally discovered asymptomatic thrombocytopenia and the probable diagnosis of ITP, no further evaluation beyond the routine history, physical examination, complete blood count, and examination of the peripheral blood smear is necessary. Specifically, anti-platelet antibody studies, imaging studies, and bone marrow biopsy are not necessary. In patients &gt;60 years of age, isolated thrombocytopenia may be the initial manifestation of one of the myelodysplastic disorders, and performance of bone marrow aspiration and biopsy may be appropriate (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Myelodysplastic syndrome'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Isolated thrombocytopenia may be the initial manifestation of systemic autoimmune disorders, such as systemic lupus erythematosus (SLE) and the anti-phospholipid antibody syndrome. In general, the characteristic serologic abnormalities of these syndromes (eg, anti-nuclear antibodies, anti-phospholipid antibodies), are commonly present in patients with otherwise typical ITP. On the other hand, tests for these autoantibodies are not necessary in patients with isolated thrombocytopenia and no signs or symptoms suggestive of SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Liver disease with hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, isolated thrombocytopenia may be the initial manifestation of chronic liver disease with portal hypertension and congestive splenomegaly (hypersplenism). Platelet counts are usually",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL",
"    </span>",
"    in such patients and the spleen is characteristically enlarged to palpation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Myelodysplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelodysplastic syndromes may present with isolated thrombocytopenia. A small percent of patients with clinical courses characteristic of chronic ITP may have clonal hematopoiesis on further testing, indicating that their thrombocytopenia is actually due to myelodysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4008100#H4008100\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Complete blood count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is much more common for patients with myelodysplasia to have anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukopenia in addition to thrombocytopenia, rather than isolated thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital thrombocytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with incidentally discovered asymptomatic thrombocytopenia, congenital disorders should always be considered. Many congenital thrombocytopenias are associated with the presence of giant platelets; some disorders also have characteristic neutrophil inclusions and other congenital anomalies.",
"   </p>",
"   <p>",
"    The consideration of congenital thrombocytopenia should be greater in patients who have a prolonged history of asymptomatic abnormal platelet counts or a family history of thrombocytopenia. Patients with congenital thrombocytopenia are typically diagnosed and followed for many years with the presumptive diagnosis of ITP, until another family member is discovered to have a low platelet count. The congenital thrombocytopenias are described in detail elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11382687\">",
"    <span class=\"h2\">",
"     Follow-up of minimal asymptomatic thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short- and long-term natural history of patients with isolated asymptomatic minimal thrombocytopenia was studied prospectively in 217 apparently healthy individuals who had incidentally discovered platelet counts between 100,000 and",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    and were referred to a hematology center [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/2\">",
"     2",
"    </a>",
"    ]. At the end of six months of observation, 23 (11 percent) had achieved normal platelet counts, two developed refractory anemia, and one developed systemic lupus erythematosus. The remaining 191 patients (88 percent) maintained platelet counts",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL",
"    </span>",
"    during this period without other signs of disease becoming evident.",
"   </p>",
"   <p>",
"    In long-term follow-up of these 191 patients, 13 developed normal platelet counts, 12 developed consistent platelet counts less than",
"    <span class=\"nowrap\">",
"     100,000/microL,",
"    </span>",
"    13 developed an autoimmune disease other than immune thrombocytopenia (ITP), and 18 developed unrelated disorders or died of cardiovascular accidents. The remaining 135 patients (71 percent of the group of 191 patients) continued to have stable borderline thrombocytopenia or were lost to follow-up with stable platelet counts",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL.",
"    </span>",
"    The 10-year probability of developing a consistent platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL,",
"    </span>",
"    that was described in this study as ITP or an autoimmune disorder other than ITP was 6.9 and 12.0 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC ISOLATED THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with symptomatic isolated thrombocytopenia, manifested by petechiae, purpura, and perhaps other mucosal bleeding such as epistaxis and menorrhagia, have a more limited differential diagnosis than patients with incidentally discovered asymptomatic isolated thrombocytopenia. In the absence of any signs of systemic illness or other abnormalities of the complete blood count, only drug-induced and primary immune thrombocytopenia are important considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of suspected drug-induced thrombocytopenia is described above. Acute severe and symptomatic thrombocytopenia is the most common presentation. Recurrent acute episodes of thrombocytopenia should always be considered to be drug-induced; this pattern of thrombocytopenia is not characteristic of ITP. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Drug-induced thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Even if a drug association with the patient's thrombocytopenia is not immediately apparent, an intensive search for a drug, food, or herbal remedy as the etiology of the thrombocytopenia should be continued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a drug-related etiology is excluded by a careful drug history, then immune thrombocytopenia (ITP) is the appropriate diagnosis. A clinical course of persistent thrombocytopenia will support the diagnosis of ITP, since drug-induced thrombocytopenia should resolve promptly when the offending agent is stopped. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Primary immune thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HOSPITAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Thrombocytopenia and multisystem illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is often discovered as an unexpected abnormality in a patient hospitalized for another reason. As described for office presentations, laboratory error, pseudothrombocytopenia, and drug-induced thrombocytopenia must always be considered. Primary immune thrombocytopenia (ITP) is not a diagnostic consideration in such settings, since ITP is, by definition, not associated with multisystem illness.",
"   </p>",
"   <p>",
"    Thrombocytopenia is a common abnormality among patients in intensive care units (ICUs). Often the etiology of thrombocytopenia is either unknown or multifactorial and extensive evaluation may not be particularly helpful. Thrombocytopenia in ICU patients is a critical prognostic indicator, but only because thrombocytopenia is typically associated with severe infection. However, thrombocytopenia as a cause of major bleeding contributing to death is uncommon in ICU patients.",
"   </p>",
"   <p>",
"    The possibility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia should not be overlooked; this condition can be associated with minimal use of heparin, such as heparin flushes to keep open indwelling vascular access lines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H2#H2\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Drug-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to review all of the drugs that have been given to a patient who has developed thrombocytopenia while in the hospital. This is an especially important consideration in patients with recurrent acute thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Antibiotics",
"      </strong>",
"      &mdash; Antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"       piperacillin",
"      </a>",
"      are a frequent cause of unexpected drug-induced thrombocytopenia, occasionally associated with bleeding.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      &mdash; In hospitalized patients receiving heparin, heparin-induced thrombocytopenia is an important consideration, often as part of a multi-system heparin-induced disorder, often associated with venous and arterial thromboses, rather than bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other drugs",
"      </strong>",
"      &mdash; While over 1000 drugs have been suspected as causing thrombocytopenia, the evidence is most strong for only 24 (",
"      <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"       table 3",
"      </a>",
"      ). The patient&rsquo;s drug list should be checked against those in this table. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H11#H11\">",
"       \"Drug-induced thrombocytopenia\", section on 'Evidence for particular drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Liver disease with hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic liver disease and portal hypertension causing congestive splenomegaly inevitably have thrombocytopenia. The platelet count is typically in the range of 50,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL,",
"    </span>",
"    levels not usually associated with bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic infections and advanced malignancies with disseminated intravascular coagulation (DIC) are frequently associated with thrombocytopenia as well as coagulation abnormalities (",
"    <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"     table 4",
"    </a>",
"    ). Petechiae and ecchymoses are common in conjunction with blood oozing from wound sites, intravenous lines, catheters, and, in some cases, mucosal surfaces. Bleeding can be life-threatening if it involves the gastrointestinal tract, lungs, or central nervous system. In patients who develop DIC after surgical procedures, hemorrhage may develop around indwelling lines, catheters, drains, and tracheostomies, and blood may accumulate in serous cavities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pregnancy-related syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the common asymptomatic and incidentally discovered gestational thrombocytopenia described for office presentations, pregnant women at the time of delivery, or within several days following delivery, may have acute and severe thrombocytopenia as a manifestation of preeclampsia, the HELLP syndrome (",
"    <strong>",
"     h",
"    </strong>",
"    emolysis,",
"    <strong>",
"     e",
"    </strong>",
"    levated",
"    <strong>",
"     l",
"    </strong>",
"    iver enzymes, and",
"    <strong>",
"     l",
"    </strong>",
"    ow",
"    <strong>",
"     p",
"    </strong>",
"    latelets), or disseminated intravascular coagulation caused by abruptio placentae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to recognize that pregnancy-related thrombocytopenic syndromes typically resolve following delivery. Careful follow-up for several days should document gradual recovery, in order to exclude thrombotic thrombocytopenic purpura (TTP), which may either not improve or worsen after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H15#H15\">",
"     \"Thrombocytopenia in pregnancy\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link&amp;anchor=H20#H20\">",
"     \"HELLP syndrome\", section on 'Postpartum course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) must be considered in any patient who is acutely ill with severe thrombocytopenia and anemia. Other organ dysfunction, such as neurologic signs or renal failure, may not be present initially, and fever is uncommon. An acute episode of TTP-HUS may be &ldquo;triggered&rdquo; by another acute illness and therefore may occur suddenly and unexpectedly in patients hospitalized for other disorders, such as cardiac surgery or pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a practical matter, only thrombocytopenia and microangiopathic hemolytic anemia without another clinically apparent etiology are required to suspect the diagnosis of TTP-HUS and to initiate plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PATIENT MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11115826\">",
"    <span class=\"h2\">",
"     Overall management goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of thrombocytopenia is guided by an understanding of its etiology and clinical course, with the principal treatment goal being prevention of bleeding, since correction of the underlying cause may not always be possible (eg, congenital thrombocytopenia), or may not be necessary (eg, mild to moderate immune thrombocytopenia). The fundamental management principle for such patients is to maintain a safe platelet count, which may vary with different causes of thrombocytopenia and different clinical settings (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Definition of a safe platelet count'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In patients with thrombocytopenia as part of a multi-system disorder (eg, disseminated intravascular coagulation, acute myeloid leukemia, HIV infection), treatment of the primary disorder is the fundamental management principle. For such patients, maintenance of a safe platelet count via the use of platelet transfusions may be only a small part of the overall treatment plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Need for hematologic consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the cause of the thrombocytopenia (of any degree of severity) is not clear after retesting and initial evaluation, hematologic consultation is warranted. Attention to the rest of the complete blood count, white cell differential, and description of the peripheral blood smear is of paramount importance in assuring that disorders such as myelodysplastic syndrome, acute leukemia, and microangiopathy (eg, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura) are not present. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Repeat testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Definition of a safe platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"safe\" platelet count is a common issue for discussion among physicians and with their patients. It is an imprecise concept with no evidence-based recommendations, varying from disorder to disorder and even from patient to patient with the same disorder. The concept of a \"safe\" platelet count can only be considered if all other aspects of hemostasis are normal. For example, in a patient with liver disease, a low platelet count may be only one of several hemostatic abnormalities while thrombocytopenia, commonly secondary to congestive splenomegaly, is rarely related to bleeding problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H525348817#H525348817\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Problem overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However imprecise, the following is a general guideline for the relationship between the platelet count and bleeding phenomena (",
"    <a class=\"graphic graphic_figure graphicRef72370 \" href=\"UTD.htm?19/27/19901\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with platelet counts",
"      <span class=\"nowrap\">",
"       &gt;50,000/microL",
"      </span>",
"      will most likely never be recognized unless a platelet count is performed, as this platelet count level appears adequate for hemostasis in virtually all circumstances.",
"     </li>",
"     <li>",
"      Patients with platelet counts in the range of 30,000 to",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      rarely have purpura, even with significant trauma.",
"     </li>",
"     <li>",
"      Patients with persistent platelet counts of 10,000 to",
"      <span class=\"nowrap\">",
"       30,000/microL",
"      </span>",
"      may be asymptomatic, even with the usual trauma of everyday activities. However these patients may be at risk for excessive bleeding following more extensive trauma.",
"     </li>",
"     <li>",
"      Spontaneous bleeding symptoms typically do not occur unless platelet counts are",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL.",
"      </span>",
"      Such patients commonly have some spontaneous bruises and some petechiae, but even they may be entirely asymptomatic on occasion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that the platelet count must be",
"    <span class=\"nowrap\">",
"     &lt;5000/microL",
"    </span>",
"    (ie, less than 2 percent of normal) to cause critical spontaneous bleeding. These general concepts correlating platelet counts and bleeding risks seem to apply to all thrombocytopenic disorders, although patients who have thrombocytopenia primarily caused by increased peripheral platelet destruction (eg, primary immune thrombocytopenia, ITP) seem to have less risk for bleeding with severe thrombocytopenia than patients for whom marrow failure is the principal cause of the thrombocytopenia (eg, aplastic anemia).",
"   </p>",
"   <p>",
"    Patients with ITP are continually producing platelets. Even though the rate of their production may be limited, their circulating platelets are young and hemostatically active (",
"    <a class=\"graphic graphic_figure graphicRef72370 \" href=\"UTD.htm?19/27/19901\">",
"     figure 1",
"    </a>",
"    ). On the other hand, platelets in patients with marrow failure syndromes are generally older, and may be both less hemostatically active as well as dysfunctional. Isolated thrombocytopenia caused by marrow failure is very rare; management of these syndromes will be described below in the discussion of patients with multi-system illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h4\">",
"     Activity restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations of patients with chronic ITP who have had severe thrombocytopenia for many years provide the basis for reasonable recommendations concerning activity restrictions in the patient with thrombocytopenia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are otherwise healthy and have no manifestations of petechiae or purpura may require no activity restrictions, even if severe thrombocytopenia is present. These recommendations require individual considerations, such as participation in contact sports. For example, any degree of thrombocytopenia, however mild, may exclude a person from a career such as an Air Force pilot or race car driver.",
"     </li>",
"     <li>",
"      Patients with moderate thrombocytopenia probably should not participate in extreme athletics such as boxing, rugby, and karate. However, no restrictions are necessary for usual activities.",
"     </li>",
"     <li>",
"      Patients who have had ITP for many years, and may have severe yet minimally symptomatic thrombocytopenia, such as platelet counts",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef72370 \" href=\"UTD.htm?19/27/19901\">",
"       figure 1",
"      </a>",
"      ), may initially restrict their activities. However, these patients often learn that no restriction is necessary and may even resume vigorous athletics. Even if their physician advises against athletic competition, horseback riding, skiing, and other potentially traumatic activities, patients will eventually do all of these things if they choose. This is especially true for adolescents and young adults. Prudence is the only guide. Excessive mandated restrictions will only restrict the information the patient provides to his physician, and will likely not restrict activities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h4\">",
"     Invasive procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is traditionally stated that a platelet count greater than 40,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    provides safety for interventional procedures such as lumbar puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In certain procedures where bleeding risks are greater, or the risk of complications from minor bleeding is high, a platelet count greater than 80,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    is often required by surgeons (especially neurosurgeons) or anesthesiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A common situation is epidural anesthesia for obstetric delivery, for which anesthesiologists often require a platelet count of at least",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/13\">",
"     13",
"    </a>",
"    ]. While there is some flexibility in individual circumstances, anesthesiologists and surgeons will have the last word. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Definitions and normal values'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558384448#H558384448\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Preparation for an invasive procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H382870465#H382870465\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Ordering platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain procedures, such as bone marrow",
"    <span class=\"nowrap\">",
"     aspiration/biopsy,",
"    </span>",
"    in which hemostasis can be supported local pressure, can be performed safely in patients with severe thrombocytopenia. For common situations, such as childbirth and tooth extractions, a platelet count of 30,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    is often sufficient. For patients with lower platelet counts, some measure to increase the platelet count immediately prior to the procedure may be required. For a patient with chronic ITP, for example, a short course of glucocorticoids, such as one week of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    is typically sufficient to increase the platelet count to provide hemostasis; prednisone can be abruptly discontinued afterwards. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Life-threatening bleeding and surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients unresponsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or for procedures that need to be urgently performed, intravenous immunoglobulin (IVIG) in a dose of 0.4 to 1",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    will increase the platelet count to a safe level in one to three days in most patients. However IVIG is an extremely expensive alternative. Platelet transfusions can be used in urgent situations. Although platelet survival in the circulation of patients with ITP and other disorders with accelerated platelet destruction may not be normal, platelet transfusion, supplemented as necessary with high-dose glucocorticoids or IVIG, nearly always provides prompt satisfactory hemostasis, if only for a short duration. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Platelet transfusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11382895\">",
"    <span class=\"h3\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;ITP provides the paradigm for persistent isolated thrombocytopenia. The only goal of treatment is to prevent serious bleeding. A normal platelet count is not a goal of treatment for ITP. In patients with significant bleeding symptoms, treatment is essential. Patients with asymptomatic thrombocytopenia may be treated if the thrombocytopenia is severe and the risk for bleeding seems great. However when treatments are ineffective and significant bleeding does not occur, the patient will recognize that treatment is worse than the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/15\">",
"     15",
"    </a>",
"    ]. In these patients, careful observation without treatment is the best management, even when the platelet count is extremely low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'General therapeutic principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelet transfusions are not indicated in patients with thrombocytopenia caused by increased peripheral platelet destruction unless critical bleeding occurs, or unless an urgent invasive procedure is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395722#H558395722\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Immune thrombocytopenic purpura (ITP)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8795830\">",
"    <span class=\"h3\">",
"     Safety of treatment with antiplatelet agents and anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thrombocytopenia may have appropriate indications for the use of antithrombotic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) or anticoagulants. However, there is no evidence to guide the decisions for when these agents are safe to use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/17\">",
"     17",
"    </a>",
"    ]. As described above for invasive procedures, platelet counts of at least 30,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    are generally sufficient to provide hemostasis when platelet function is assumed to be normal. When platelet function is partially impaired by the use of an antiplatelet agent, the risk of bleeding is increased, but it may not be excessive at platelet counts over",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The use of anticoagulants is a more difficult decision because all anticoagulant agents have an inherent risk for severe bleeding, and it must be assumed that this risk will be increased in the presence of thrombocytopenia. Therefore it may be prudent to require a higher platelet threshold for the use of anticoagulant agents, such as a platelet count",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H12#H12\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Hospitalized medical patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H23758764#H23758764\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Bleeding risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physician must make individual assessments for each patient, weighing the relative risks for bleeding and thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a general principle is that most bleeding symptoms are treatable, while thromboses may cause irreversible damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Emergency management of critical bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent management of a patient with severe thrombocytopenia and critical bleeding requires immediate transfusion of platelets, regardless of the etiology of the thrombocytopenia. Adjunctive treatment with high doses of glucocorticoids, such as 1000 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and IVIG (0.4 to 1 gm) is also appropriate. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Life-threatening bleeding and surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395184#H558395184\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Actively bleeding patient'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H382870465#H382870465\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Ordering platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Thrombocytopenia with multi-system illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to management issues for otherwise healthy patients with isolated thrombocytopenia, a low platelet count in a hospitalized patient with other associated disorders is usually not a major management consideration. However, issues related to invasive procedures may be important (see",
"    <a class=\"local\" href=\"#H33\">",
"     'Invasive procedures'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Platelet transfusions may be necessary for management of bleeding symptoms in patients with severe thrombocytopenia. However platelet transfusions are not necessary in patients without bleeding symptoms unless the platelet count is",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/18\">",
"     18",
"    </a>",
"    ]. This practice has been established from studies of patients with acute leukemia receiving intensive chemotherapy and who require platelet transfusion support until marrow function recovers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395341#H558395341\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Specific clinical scenarios'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of patients with marrow failure syndromes is different from management of patients with chronic severe ITP. Platelets of patients with marrow failure syndromes may be less effective than those in chronic ITP; therefore these patients may have more bleeding symptoms than a patient with ITP and a similar platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19385/abstract/19\">",
"     19",
"    </a>",
"    ]. Most patients with thrombocytopenia secondary to a malignancy or aplastic anemia are receiving treatment or awaiting further treatment, therefore regular platelet transfusion support is more practical, since only a temporary duration of support may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15714726\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of isolated",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      thrombocytopenia in the office or outpatient setting include laboratory error, pseudothrombocytopenia, drug-induced thrombocytopenia, post-viral infection thrombocytopenia, and immune thrombocytopenia (",
"      <a class=\"graphic graphic_table graphicRef50310 \" href=\"UTD.htm?29/60/30668\">",
"       table 1",
"      </a>",
"      ). The approach to these patients includes the following (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Isolated asymptomatic thrombocytopenia'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Repeat testing to rule out laboratory error",
"     </li>",
"     <li>",
"      Complete history, including an extensive history of all drugs, herbal preparations, over-the-counter medications (",
"      <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60296 \" href=\"UTD.htm?21/20/21836\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evaluation of the complete blood count and peripheral blood smear",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For outpatients who present with",
"      <strong>",
"       symptomatic",
"      </strong>",
"      isolated thrombocytopenia (eg, petechiae, purpura, epistaxis), no signs of systemic illness, and no abnormalities of the complete blood count, only drug-induced and primary immune thrombocytopenia are important diagnostic considerations. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Symptomatic isolated thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombocytopenia is often an unexpected abnormality in a patient hospitalized for another reason. As described for office presentations, pseudothrombocytopenia and drug-induced thrombocytopenia must always be considered. Other common causes include disseminated intravascular coagulation due to infection, liver disease, and thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hospital presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fundamental management principle for thrombocytopenic patients is to prevent bleeding by maintaining a &ldquo;safe&rdquo; platelet count. This will depend upon the underlying disorder, presence of co-morbidities, invasive procedures to be performed, and need for emergency control of bleeding. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Patient management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/1\">",
"      Buckley MF, James JW, Brown DE, et al. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost 2000; 83:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/2\">",
"      Stasi R, Amadori S, Osborn J, et al. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006; 3:e24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/3\">",
"      Achterbergh R, Vermeer HJ, Curtis BR, et al. Thrombocytopenia in a nutshell. Lancet 2012; 379:776.",
"     </a>",
"    </li>",
"    <li>",
"     www.ouhsc.edu/platelets (Accessed on May 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/5\">",
"      Nguyen L, Reese JA, George JN. Drug-induced thrombocytopenia. An updated review, 2010. Drug Safety 2011; 34:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/6\">",
"      Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/7\">",
"      George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/8\">",
"      Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/9\">",
"      Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/10\">",
"      Rousan TA, Aldoss IT, Cowley BD Jr, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol 2010; 85:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/11\">",
"      Swisher KK, Doan JT, Vesely SK, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007; 92:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/12\">",
"      British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/13\">",
"      van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010; 148:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/14\">",
"      Sarode R, Refaai MA, Matevosyan K, et al. Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. Transfusion 2010; 50:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/15\">",
"      George JN, Vesely SK. Immune thrombocytopenic purpura--let the treatment fit the patient. N Engl J Med 2003; 349:903.",
"     </a>",
"    </li>",
"    <li>",
"     See \"Christy's story\" and \"Crystal's story\" for examples www.ouhsc.edu/platelets (Accessed on May 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/17\">",
"      Tufano A, Guida A, Di Minno MN, et al. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/18\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19385/abstract/19\">",
"      Psaila B, Bussel JB, Frelinger AL, et al. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost 2011; 9:2302.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6864 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19385=[""].join("\n");
var outline_f18_59_19385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15714726\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11328209\">",
"      WHAT IS A LOW PLATELET COUNT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OFFICE PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ISOLATED ASYMPTOMATIC THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory error",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Repeat testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pseudothrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gestational thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Liver disease with hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital thrombocytopenias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11382687\">",
"      Follow-up of minimal asymptomatic thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SYMPTOMATIC ISOLATED THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HOSPITAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Thrombocytopenia and multisystem illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Liver disease with hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pregnancy-related syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11115826\">",
"      Overall management goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Need for hematologic consultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Definition of a safe platelet count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Activity restrictions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Invasive procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11382895\">",
"      - Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8795830\">",
"      - Safety of treatment with antiplatelet agents and anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Emergency management of critical bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Thrombocytopenia with multi-system illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15714726\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6864|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/27/19901\" title=\"figure 1\">",
"      Platelet count and bleeding in ITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6864|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 1\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6864|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/60/30668\" title=\"table 1\">",
"      Presentations thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/20/21836\" title=\"table 2\">",
"      Sources of quinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/3/36924\" title=\"table 3\">",
"      Drugs associated with immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/15/35067\" title=\"table 4\">",
"      Acute versus chronic DIC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_59_19386="Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)";
var content_f18_59_19386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19386/contributors\">",
"     Dennis J Ahnen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19386/contributors\">",
"     Lisen Axell, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19386/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/59/19386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/59/19386/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/59/19386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC), is the most common of the inherited colon cancer susceptibility syndromes. The use of the name HNPCC can be misleading in that this disorder predisposes to colon cancer and a variety of other cancers. As a result, the previously used name Lynch syndrome (after Dr. Henry Lynch, who did much to characterize and emphasize the importance of this familial syndrome) is being used more commonly.",
"   </p>",
"   <p>",
"    Lynch syndrome is an autosomal dominant disorder that is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. It accounts for 2 to 3 percent of all colon cancer cases and similarly is responsible for about 2 percent of endometrial cancers. Lynch syndrome is characterized by significantly increased risk for colon cancer and endometrial cancer as well as a smaller risk of several other associated cancers.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnostic criteria, and genetics of Lynch syndrome will be reviewed here. Surveillance and screening strategies for Lynch syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for hereditary colorectal cancer and genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Lynch syndrome have a markedly increased risk of colorectal cancer (",
"    <a class=\"graphic graphic_picture graphicRef51584 \" href=\"UTD.htm?26/24/27011\">",
"     picture 1",
"    </a>",
"    ), endometrial cancer, and several other cancers including ovarian, upper urologic tract, gastric, small bowel,",
"    <span class=\"nowrap\">",
"     biliary/pancreatic,",
"    </span>",
"    skin (sebaceous adenomas and carcinomas and keratoacanthomas), and brain cancers. The cancer risk in Lynch syndrome varies depending on",
"    <span class=\"nowrap\">",
"     geographic/environmental",
"    </span>",
"    factors (for example, gastric cancer is a more common Lynch-associated cancer in countries such as China and Korea with a high sporadic prevalence of that disease). Similarly, the age-incidence and spectrum of cancers in Lynch syndrome vary significantly based upon the MMR gene mutated; this will be described in more detail after the genetics of the syndrome is presented.",
"   </p>",
"   <p>",
"    As in most other familial cancer syndromes, early age of onset and multiplicity of cancers have been considered hallmarks of Lynch syndrome. In registry-based Lynch syndrome series, the mean age at initial colorectal cancer diagnosis is about 45 years, compared to around age 65 for sporadic colorectal cancer, and some Lynch syndrome patients present with colorectal cancer in their twenties. Similarly, the mean age of uterine cancer in Lynch syndrome is about 50 years, which is about 10 years younger than the average age of sporadic uterine cancer.",
"   </p>",
"   <p>",
"    Registry-based reports are likely biased because the families enrolled in high risk clinics are frequently identified by the presence of young onset cancers. One series reported that if probands were excluded from that analysis, the median age at diagnosis of colorectal cancer and endometrial cancer in Lynch syndrome gene carriers would be over 60 years, suggesting that this syndrome also needs to be considered in older individuals with a strong cancer family history [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiplicity of cancers is also a hallmark of Lynch syndrome. About 7 to 10 percent of identified Lynch family members have had more than one cancer by the time of diagnosis (synchronous colorectal cancers). Individuals with Lynch syndrome are also at risk for metachronous colorectal cancer, which is usually defined as a primary colorectal cancer diagnosed more than 12 months after the first diagnosis of primary colorectal cancer. Approximately 20 to 40 percent of patients with Lynch syndrome related colorectal cancer have been reported to develop metachronous colorectal cancer after initial resection if a subtotal colectomy is not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/3\">",
"     3",
"    </a>",
"    ], and the risk increases over time. In one study, the cumulative risk of metachronous colorectal cancer in patients with Lynch syndrome who had undergone a segmental resection for the first colorectal cancer was 16 percent at 10 years, 41 percent at 20 years, and 62 percent at 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, clustering of more than one Lynch-associated cancer (ie, colorectal and uterine) in an individual patient should also raise suspicion of Lynch syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Colorectal cancers in Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of developing colon cancer in Lynch syndrome is approximately 70 percent in most familial cancer registry databases, but these risk estimates may be artificially high due to ascertainment bias [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/5\">",
"     5",
"    </a>",
"    ]. Rates ranging from 25 to 75 percent have been described in various reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/6\">",
"     6",
"    </a>",
"    ]. The overall colorectal cancer rate is moderately higher in men than in women, and although the age of onset of colon cancer varies with the genotype of Lynch syndrome (see below), it is younger than that found in sporadic colorectal cancer.",
"   </p>",
"   <p>",
"    The colorectal cancers in Lynch syndrome differ from typical sporadic colorectal cancers in location, histology, and natural history. Like most sporadic colorectal cancers, Lynch cancers appear to evolve from adenomas, but when detected the adenomas tend to be larger, flatter, are more often proximal, and more commonly have high-grade dysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    villous histology than sporadic adenomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adenoma-carcinoma sequence is thought to progress much more rapidly in Lynch syndrome and new cancers have occurred within two to three years after what appeared to be a negative colonoscopy. Like the adenomas, colorectal cancers in Lynch syndrome are also more commonly proximal; nearly 70 percent of first colorectal cancers in Lynch syndrome arise proximal to the splenic flexure whereas only about 40 to 50 percent of sporadic colorectal cancers are in this region.",
"   </p>",
"   <p>",
"    Lynch colorectal cancers sometimes often contain tumor infiltrating lymphocyte and may contain an intense \"Crohn's-like\" lymphocytic infiltrate at their periphery which is uncommon in sporadic colorectal cancers. They are also more commonly poorly differentiated, and are more commonly mucinous than sporadic colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/7\">",
"     7",
"    </a>",
"    ]. Despite their apparently aggressive histologic characteristics, the overall five-year survival rates in affected family members is better than that seen in sporadic colorectal cancer, suggesting that the biology and natural history of Lynch-related tumors is fundamentally different from that of sporadic colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Extracolonic cancers in Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common extracolonic tumor in Lynch syndrome is endometrial carcinoma. The prevalence of endometrial cancer may vary depending on which DNA repair gene is mutated but had been reported to be as high as 70 percent of female gene carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Other sites at increased risk of neoplasm formation in Lynch syndrome include the ovary, stomach, small bowel, pancreas, hepatobiliary system, renal pelvis, and ureter.",
"   </p>",
"   <p>",
"    The frequency of extracolonic cancers in Lynch syndrome varied from 2 to 20 percent in different reports. The cumulative risk is related to the specific MMR mutation (",
"    <a class=\"graphic graphic_table graphicRef52285 \" href=\"UTD.htm?19/25/19869\">",
"     table 1",
"    </a>",
"    ). There is some debate about whether prostate or breast cancers might be part of the Lynch syndrome; these sites are currently not included as part of the diagnostic group of Lynch-associated cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Since most patients with Lynch syndrome who develop breast cancer do so after the age of 50 years, standard screening approaches for breast cancer are likely appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H4636122#H4636122\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Hereditary nonpolyposis colorectal cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H35#H35\">",
"     \"Screening for breast cancer\", section on 'Recommendations for screening by expert groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible association of breast cancer with Lynch syndrome has been suggested in studies of MMR proteins and microsatellite instability in breast cancer specimens. Studies have demonstrated loss of MMR proteins or microsatellite instability in breast cancer specimens from known MLH1 and MSH2 carriers, suggesting a causal role of MMR mutations. In one summary of the literature, 26 of 37 (70.3 percent) breast cancers in MMR mutation carriers demonstrated microsatellite instability and 16 of 22 (72.7 percent) demonstrated absent MMR protein [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Muir-Torre and Turcot variants of Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two variants of Lynch syndrome that in the past had been considered distinct entities: Muir-Torre (Lynch syndrome with associated sebaceous tumors, cutaneous keratoacanthomas, and visceral carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]) and Turcot syndrome (Lynch syndrome with associated brain tumors, typically gliomas). The term Turcot syndrome has also been used for those individuals with familial adenomatous polyposis and brain tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .) It is now clear that the Muir-Torre and Turcot groups are not separate syndromes from Lynch syndrome since they occur in families with known DNA MMR gene mutations. These families reflect the associated risk of these extracolonic cancers (brain, sebaceous tumors, skin acanthomas, and visceral carcinomas) in some individuals with Lynch syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENETICS OF LYNCH SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of the cancer risk and some aspects of management of Lynch syndrome vary depending upon which specific DNA MMR gene mutation is causing the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     The mismatch repair (MMR) system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the DNA MMR system is to maintain genomic integrity by correcting base substitution mismatches and small insertion-deletion mismatches that are generated by errors in base pairing during DNA replication. Normal mismatch repair requires the coordinated function of several different gene products.",
"   </p>",
"   <p>",
"    The mismatch repair genes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MSH2 (MutS homolog 2), which is located on chromosome 2p16",
"     </li>",
"     <li>",
"      MLH1 (MutL homolog 1), which is located on chromosome 3p21",
"     </li>",
"     <li>",
"      PMS1 and PMS2 (postmeiotic segregation 1 and 2), which are located on chromosomes 2q31 and 7p22, respectively",
"     </li>",
"     <li>",
"      MSH6 (MutS homolog 6), which is located on chromosome 2p16",
"     </li>",
"     <li>",
"      MLH3, (MutL homolog 3), a mismatch repair gene that interacts with MLH1, but the role of MLH3 in Lynch syndrome is not yet clear [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MMR system recognizes base-pair mismatches and repairs them. The recognition is done by two heterodimeric protein complexes termed MutS-alpha and MutS-beta. MutS-alpha is a heterodimer of MSH2 and MSH6 proteins and MutS-beta is an",
"    <span class=\"nowrap\">",
"     MSH2/MSH3",
"    </span>",
"    heterodimer. Either the",
"    <span class=\"nowrap\">",
"     MSH2/6",
"    </span>",
"    or the",
"    <span class=\"nowrap\">",
"     MSH2/3",
"    </span>",
"    pair can recognize",
"    <span class=\"nowrap\">",
"     insertion/deletion",
"    </span>",
"    loops that contain more than two bases but the",
"    <span class=\"nowrap\">",
"     MSH2/6",
"    </span>",
"    pair preferentially recognizes single base-base mispairs and small (one to two base) insertion-deletion loops [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The repair components of the MMR system consist of three other heterodimer pairs termed MutL-alpha, MutL-beta, and MutL-gamma. MutL-alpha is a heterodimer of MLH1 and PMS2, MutL-beta is a",
"    <span class=\"nowrap\">",
"     MLH1/PMS1",
"    </span>",
"    heterodimer, and MutL-gamma is a",
"    <span class=\"nowrap\">",
"     MLH1/MLH3",
"    </span>",
"    heterodimer.",
"   </p>",
"   <p>",
"    It has been shown that large deletions in the 3' end of the EpCAM gene (previously called TACSTD1) can cause inactivation of MSH2. The EpCAM gene is upstream of MSH2. The large deletions disrupt the 3' end of EpCAM leading to transcriptional read-through into and subsequent epigenetic silencing of its neighboring gene, MSH2, causing Lynch syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Consequences of the defective mismatch repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivation of both alleles of one of the MMR genes leads to defective MMR. As a general rule, patients with HNPCC have a germline mutation in one allele of a MMR gene and the second allele is inactivated by mutation, loss of heterozygosity, or epigenetic silencing by promoter hypermethylation.",
"   </p>",
"   <p>",
"    Biallelic inactivation of MMR genes causes an increased mutation rate (genomic instability) due to failure to repair the DNA mismatches that occur commonly during normal DNA synthesis (about one in every 10",
"    <sup>",
"     6",
"    </sup>",
"    bases). DNA mismatches commonly occur in regions of repetitive nucleotide sequences called microsatellites. Thus, a characteristic feature of loss of mismatch repair in tumors is the expansion or contraction of these microsatellite regions in the tumor compared to normal tissue; this genetic alteration is termed microsatellite instability and is a molecular signature of Lynch-associated cancers (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Microsatellite instability: The molecular signature of Lynch syndrome cancers'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The increased mutation rate that results from loss of mismatch repair leads to alterations in nucleotide repeats in many genes, including some that control cell growth (TGF beta and IGF receptors) or regulate apoptotic cell death (Caspase 5, Bax), and some of the DNA mismatch repair genes themselves (hMSH3, hMSH6) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/23\">",
"     23",
"    </a>",
"    ]. Accumulation of mutations in these cancer related genes is thought to drive the process of carcinogenesis in Lynch syndrome.",
"   </p>",
"   <p>",
"    Of the six different MMR genes, mutations in MSH2 or MLH1 are thought to account for about 90 percent of the heterozygous germline mutations that have been identified in patients with Lynch syndrome, MSH6 mutations are thought to account for most of the remainder, and PMS2 mutations have been described in relatively few Lynch families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Genotype/phenotype associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appear to be substantial differences in the clinical features of Lynch syndrome depending upon which MMR gene is mutated in the germline. The clinical features described in most series are dominated by families with MLH1 and MSH2 mutations since they are the most common disease-causing mutations.",
"   </p>",
"   <p>",
"    The overall cancer risk (about 80 percent) and the colorectal cancer risk (50 to 70 percent) is similar in MLH1 and MSH2 families but the risk of endometrial and other extracolonic cancers in some, but not all, studies appears to be substantially higher in MSH2 families (",
"    <a class=\"graphic graphic_table graphicRef52285 \" href=\"UTD.htm?19/25/19869\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/6,24,25\">",
"     6,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families with MSH6 and possibly PMS2 mutations appear to have an attenuated cancer phenotype (a later age of cancer diagnosis and a lower penetrance) compared to MLH1 and MSH2 families (",
"    <a class=\"graphic graphic_table graphicRef52285 \" href=\"UTD.htm?19/25/19869\">",
"     table 1",
"    </a>",
"    ). As an example, in one series of families with MSH6 mutations, the women had a lower risk of colorectal cancer and a higher risk of endometrial cancer than women with MSH2 or MLH1 mutations. In both men and women, the age of onset of colorectal cancer was later than in MSH2 or MLH1 mutation carriers and women had a much lower risk of colon cancer than men (",
"    <a class=\"graphic graphic_table graphicRef52285 \" href=\"UTD.htm?19/25/19869\">",
"     table 1",
"    </a>",
"    ). Another report estimated that the cumulative cancer risk to age 70 in patients with PMS2 mutations was only 15 to 20 percent for colorectal cancer, 15 percent for endometrial cancer, and only 25 to 32 percent for any Lynch syndrome-associated cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/26\">",
"     26",
"    </a>",
"    ], suggesting a very attenuated phenotype for mutations of this DNA repair gene.",
"   </p>",
"   <p>",
"    As a result of these types of differences, MLH6 and PMS2 families may well be underrepresented in the high risk registries that typically base ascertainment by the presence of familial clustering and early age of cancer onset. More recent population-based ascertainment has suggested that the MSH6 and PMS2 families may be more common than previously thought. In one series, 20 percent of the Lynch syndrome patients identified had either MSH6 or PMS2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A database of sequence variations found in Lynch syndrome can be found on the internet (available at",
"    <a class=\"external\" href=\"file://www.insight-group.org/\">",
"     www.insight-group.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biallelic MMR deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evidence of the strong carcinogenic potential of the loss of DNA mismatch repair comes from rare cases of inheritance of biallelic mutations in the MMR genes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/28-35\">",
"     28-35",
"    </a>",
"    ]. One review described 50 cases from 30 families that were reported in published literature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/36\">",
"     36",
"    </a>",
"    ]. In contrast to Lynch syndrome in which cancers occur in the fifth or sixth decade of life, homozygous or compound heterozygous mutation carriers of MLH1, MSH2, MSH6, or PMS2 often develop hematologic and brain malignancies during childhood. Most, but not all, of these individuals had a family history of Lynch syndrome on both the maternal and paternal sides of their families.",
"   </p>",
"   <p>",
"    In addition to the cancer risk in the first two decades of life, individuals with MMR deficiency (most with homozygous or compound heterozygous MMR mutations) may have a neurofibromatosis type-1-like phenotype, presenting with caf&eacute; au lait spots, neurofibromas, Lisch nodules, and axillary freckling. One dramatic case report described a patient with a homozygous PMS2 mutation that was associated with 10 separate colorectal carcinomas, duodenal adenocarcinoma, dysmorphic features, mental retardation, and caf&eacute; au lait spots [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Microsatellite instability: The molecular signature of Lynch syndrome cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"microsatellite instability\" refers to the expansion or contraction of short repetitive DNA sequences (microsatellites) that is due to a loss of DNA mismatch repair. Tumors can be tested for microsatellite instability using polymerase chain reaction to amplify a standard panel of DNA sequences containing nucleotide repeats. If 30 percent or more of the markers show expansion or contraction of the repetitive sequences in the tumor compared to the normal mucosa from the same patient, the tumor is reported to have a high level of microsatellite instability (MSI-H).",
"   </p>",
"   <p>",
"    The presence of MSI-H in tumor tissue suggests that a defect in a DNA mismatch repair gene is present. MSI is highly sensitive for Lynch syndrome; more than 90 percent of tumor tissue from patients with Lynch syndrome show high levels of microsatellite instability (MSI-H). Importantly, MSH6-associated cancers may not be MSI-H unless mononucleotide repeats are included in the polymerase chain reaction (PCR) panel, since MSH6 is preferentially involved in the repair of mononucleotide repeats. Similarly, PMS2-associated cancers may have a lower rate of MSI-H than MLH1- or MSH2-associated cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, MSI-H status cannot be used alone as a test for Lynch syndrome cancers because the specificity of MSI-H for Lynch syndrome is low. In addition to Lynch colorectal cancers, MSI-H is found in up to 15 percent of sporadic colorectal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/7\">",
"     7",
"    </a>",
"    ]. In the sporadic group, MSI-H is typically due to loss of normal MMR due to hypermethylation of the promoter region of MLH1, one of the MMR genes. Hypermethylation of the MLH1 promoter leads to epigenetic silencing of the gene.",
"   </p>",
"   <p>",
"    The two groups of MSI-H colorectal cancers (sporadic and Lynch-associated MSI-H cancers) can be differentiated by direct measurement of the methylation status of MLH1 in the tumor, or more simply by genetic analysis of the BRAF gene. For reasons that are as yet unclear, activating mutations in BRAF are nearly universal in sporadic MSI-H colorectal cancers but are rare in Lynch cancers. The identification of a BRAF mutation in an MSI-H colorectal cancer essentially rules out Lynch syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MSI-H tumors have distinct histologic features (tumor-infiltrating lymphocytes, Crohn&rsquo;s-like lymphocytic reaction,",
"    <span class=\"nowrap\">",
"     mucin/signet",
"    </span>",
"    ring cell differentiation, and medullary growth pattern) that can be used to select patients with colorectal cancers who might have Lynch syndrome and, therefore, warrant genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/7\">",
"     7",
"    </a>",
"    ]. However, while having one or more of these pathologic features can be used to predict the probability of bearing an MSI-high tumor (sensitivity 93 percent in two independent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/7,40\">",
"     7,40",
"    </a>",
"    ]), histologic characteristics alone are insufficiently accurate for the selection of patients who warrant mutation testing for Lynch syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Mismatch repair deficiency and tumor infiltrating lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore, despite its low specificity for Lynch colorectal cancers, MSI testing remains one of the first steps to identify individuals who are at increased risk for Lynch syndrome. The Bethesda guidelines (described below) identify high risk subjects who might benefit from having their colon cancers tested for MSI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mutations in the MMR genes that cause Lynch syndrome typically result in a truncated or lost protein product. Thus, immunohistochemistry (IHC) using antibodies to the C-terminal end of the MMR proteins can be used to identify colonic tumors that have lost MMR gene products (",
"    <a class=\"graphic graphic_table graphicRef63906 \" href=\"UTD.htm?29/17/29981\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/41\">",
"     41",
"    </a>",
"    ]. Loss of immunoreactive MSH2 or MSH6 in a colorectal cancer is highly specific for Lynch syndrome but, as noted above, MLH1 can also occur in sporadic colorectal cancers with hypermethylation of the MLH1 promoter. IHC for the MMR gene products can be used with or without MSI testing as the first step in a screening protocol for individuals who may have Lynch syndrome using the Bethesda guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Bethesda guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    IHC in endometrial cancer has shown efficacy for identification of Lynch syndrome. Methylation of MLH1 can cause epigenetic MSI-H endometrial tumors but BRAF V600E mutations are not a common occurrence in endometrial tumors. IHC in other Lynch syndrome tumors has been studied less rigorously and, while abnormal tumor studies may be indicative of Lynch syndrome, normal tumor studies do not necessarily rule out Lynch syndrome. These results should be evaluated in light of the family and personal history of tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies using IHC of MSH2, MLH1, MSH6, and PMS2 have shown that it has a predictive value virtually equivalent to that of MSI testing. IHC has the added value of PMS2 and MSH6 detection (which may be missed by PCR testing for MSI), is easily available, inexpensive, and identifies the affected gene. As a result, IHC has evolved as a preferred first-line screening tool for identifying Lynch syndrome in many clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/43\">",
"     43",
"    </a>",
"    ]. However, IHC results may be construed as \"genetic information,\" and institutional discussion should determine whether to require patient consent prior to testing. Most institutions performing universal IHC testing do not require patient consent for IHC testing.",
"   </p>",
"   <p>",
"    Absent MSH2 expression can be caused by large deletions in the EpCAM gene which causes inactivation of the MSH2 gene leading to a Lynch syndrome phenotype. The EpCAM gene is upstream from MSH2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/41\">",
"     41",
"    </a>",
"    ]. As many as 20 to 25 percent of cases suspected of having a mutation in MSH2 based on absent MSH2 protein on IHC, but in which a germline mutation is not detected, can be accounted for by germline deletions in EpCAM [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usefulness of MSI and IHC testing of adenomatous polyps, hyperplastic polyps, and sessile serrated polyps in patients with known MMR mutations has also been studied. In one study of such patients, MSI-H was seen in 15 of 37 adenomatous polyps (41 percent) and absence of MMR protein expression was seen in 18 of 36 adenomatous polyps (50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/45\">",
"     45",
"    </a>",
"    ]. MSI was rarely seen in hyperplastic and sessile serrated polyps. Adenomatous polyps larger than 8 mm were significantly more likely to show MSI-H and loss of MMR protein expression. Though testing of large adenomas may have some diagnostic value for individuals suspected of having Lynch syndrome, a negative MSI or IHC test on a polyp should not be considered strong evidence against Lynch syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF INDIVIDUALS WITH LYNCH SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Amsterdam criteria (",
"    <a class=\"graphic graphic_table graphicRef59832 \" href=\"UTD.htm?3/37/3675\">",
"     table 3",
"    </a>",
"    ) have classically been used as a clinical approach to help identify families that are at high enough risk for Lynch syndrome that gene testing should be considered. However, a major limitation is their low sensitivity (about 50 percent) for Lynch syndrome. As a result, the Bethesda guidelines (",
"    <a class=\"graphic graphic_table graphicRef72965 \" href=\"UTD.htm?41/48/42763\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50889 \" href=\"UTD.htm?14/50/15148\">",
"     table 5",
"    </a>",
"    ) were developed to try to identify a larger proportion of the at-risk individuals.",
"   </p>",
"   <p>",
"    The Bethesda guidelines identify individuals with colorectal or other Lynch-associated cancers who should be tested for microsatellite instability with consideration of MMR gene testing in those with MSI-H tumors. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Microsatellite instability: The molecular signature of Lynch syndrome cancers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Multiple other strategies for identifying individuals with Lynch syndrome have been proposed including predictive models, family history instruments, routine laboratory testing of colorectal cancers, and routine testing of colorectal cancers from patients with specific risk factors (eg, age &lt;50). The relative effectiveness of these approaches continues to be debated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Amsterdam criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1990, The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer established research criteria for the diagnosis of Lynch syndrome (known as the Amsterdam criteria) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/1\">",
"     1",
"    </a>",
"    ]. These criteria were modified in 1999; the modifications are known as the Amsterdam II criteria and suggest that Lynch syndrome should be suspected in kindreds.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With",
"      <strong>",
"       three",
"      </strong>",
"      or more relatives with histologically verified Lynch syndrome-associated cancers (colorectal cancer, cancer of the endometrium or small bowel, and transitional cell carcinoma of the ureter or renal pelvis), one of whom is a first degree relative of the other two and in whom FAP has been excluded.",
"     </li>",
"     <li>",
"      With Lynch syndrome-associated cancers involving at least",
"      <strong>",
"       two",
"      </strong>",
"      generations.",
"     </li>",
"     <li>",
"      In which",
"      <strong>",
"       one",
"      </strong>",
"      or more cancers were diagnosed before the age of 50.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Amsterdam II criteria can be remembered by the \"",
"    <strong>",
"     3-2-1 rule",
"    </strong>",
"    \" (3 affected members, 2 generations, 1 under age 50) (",
"    <a class=\"graphic graphic_table graphicRef59832 \" href=\"UTD.htm?3/37/3675\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Individuals meeting the Amsterdam criteria were presumptively classified as having Lynch syndrome. However, once routine molecular analyses of cancers for MSI and genetic testing became available, it became clear that many families that met the Amsterdam II criteria did not have an identifiable MMR gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/46\">",
"     46",
"    </a>",
"    ]. As a result, Lynch syndrome is now usually defined using a genetic approach and it is recommended that the term Lynch syndrome be used to include only individuals and families known to have with a detectable MMR gene mutation. Individuals without gene testing who meet the Amsterdam II criteria may be suspected to have Lynch syndrome and may be clinically managed as such, but are no longer labeled as having Lynch syndrome unless molecular analyses confirm the diagnosis.",
"   </p>",
"   <p>",
"    Almost one-half of families meeting the Amsterdam II criteria do not have Lynch syndrome by the current definition; they do not have MSI or MMR variations associated with Lynch syndrome. Patients from families that fulfill the Amsterdam criteria but whose colorectal cancers do not have microsatellite instability appear to have a lower overall risk of cancer and do not appear to have an increased risk of endometrial or other Lynch-associated cancers, compared with those in whom MSI is present",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a MMR gene mutation is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/46\">",
"     46",
"    </a>",
"    ]. The term \"familial colorectal cancer type X\" has been suggested for this group to distinguish such patients from those with Lynch syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the relative lack of specificity of the Amsterdam criteria for Lynch syndrome, the criteria are also relatively insensitive for the identification of gene carriers. In a review of the population-based and consecutive colorectal cancer series that performed MSI and DNA MMR gene testing, only 41 percent of mutation carriers met the Amsterdam II criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/7\">",
"     7",
"    </a>",
"    ]. The Bethesda guidelines were developed to help identify a larger proportion of Lynch syndrome families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bethesda guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1996 workshop sponsored by the National Cancer Institute initially proposed a set of guidelines that were later revised in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/47\">",
"     47",
"    </a>",
"    ]. The revised Bethesda guidelines are a list of criteria that suggest Lynch syndrome in a patient with colon cancer and include features such as young colorectal cancers or strong familial clustering of colon cancer with or without other Lynch-associated cancers (",
"    <a class=\"graphic graphic_table graphicRef72965 \" href=\"UTD.htm?41/48/42763\">",
"     table 4",
"    </a>",
"    ). The guidelines recommend that patients who meet the Bethesda criteria have their colon cancers tested for microsatellite instability and that germline MMR gene testing be performed in patients found to have microsatellite unstable cancers.",
"   </p>",
"   <p>",
"    Multiple studies have evaluated test characteristics of the Bethesda guidelines for detection of patients with Lynch syndrome. In a review of Lynch syndrome cases identified from population-based and consecutive series of unselected colorectal cancers, 89 percent of all the mutation carriers met the Bethesda guidelines. However, the guidelines have low specificity; 80 percent or more of patients who meet the Bethesda guidelines will not have Lynch syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Universal testing strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the Amsterdam criteria and the Bethesda guidelines attempt to enrich the population of patients with colorectal cancer in whom a genetic cause can be identified and thus avoid the expense and implications of testing patients (and their families) with colorectal cancer in whom there is a low likelihood of uncovering a relevant mutation. Concerns that this approach may miss a substantial proportion of patients with Lynch syndrome has led some investigators to test alternative approaches such as screening all colorectal cancer for evidence of microsatellite instability or loss of MMR gene products by IHC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/27,48-51\">",
"     27,48-51",
"    </a>",
"    ]. &nbsp;A survey of United States cancer programs found that routine MSI testing of some or all colorectal cancers was being used at 71 percent of NCI-designated cancer centers, but only 15 percent of community cancer programs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest studies to compare the performance characteristics of universal tumor testing with other strategies to identify patients with Lynch syndrome included 10,206 patients with a new diagnosis of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/53\">",
"     53",
"    </a>",
"    ]. While universal tumor testing had a higher diagnostic yield compared to a &ldquo;selective strategy&rdquo; of testing individuals who met one or more Bethesda guidelines or were diagnosed with colorectal cancer prior to age 70, the incremental diagnostic yield of universal testing over the selective strategy was small (0.11 percent). Furthermore, employing the selective strategy would have resulted in 35 percent fewer colorectal cancers requiring tumor testing and 29 percent fewer cases requiring germline testing for MMR mutations.",
"   </p>",
"   <p>",
"    Another study that evaluated universal testing included 1066 patients with colorectal cancer who were selected for study regardless of the clinical features or family history surrounding the diagnosis of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/27\">",
"     27",
"    </a>",
"    ]. All patients were screened for Lynch syndrome by testing for microsatellite instability. In subjects with microsatellite unstable cancers, a relatively complex algorithm of immunohistochemistry for evidence of loss of MLH1, MSH2, MSH6, and PMS2, mutational analysis for these same genes, and methylation analysis to look for epigenetic silencing of MLH1 was performed. Of the 23 individuals found to have Lynch syndrome by mutational analysis, only three met the Amsterdam criteria, 18 met the Bethesda criteria and five did not meet either the Amsterdam criteria or the Bethesda guidelines.",
"   </p>",
"   <p>",
"    This study also demonstrates both the benefits and weaknesses of such a screening approach. It illustrates that using the Amsterdam or Bethesda criteria alone may miss a substantial portion of patients with Lynch syndrome (22 percent in this series) but that it would require a complex and expensive effort to find the additional subjects. Only five additional individuals from the entire cohort of 1066 subjects (one-half of 1 percent) were identified by routine molecular analysis of all colon cancers than would have been detected by using the Bethesda criteria (of interest, three of these five had colorectal cancer between age 50 and 60). Another way to look at this is that the number needed to test in order to identify one additional Lynch syndrome gene carrier was 213.",
"   </p>",
"   <p>",
"    Studies suggest that universal tumor testing of all colorectal cancers for Lynch syndrome may be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In one study, IHC followed by BRAF mutation testing was the preferred tumor testing strategy with an incremental cost-effectiveness ratio of $36,200 per life-year gained [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the cost-effectiveness of testing depended on the participation rate of at-risk relatives in genetic testing with three relatives required to meet a cost-effectiveness threshold of $50,000 per life-year gained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Algorithms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several algorithms for evaluation of patients with suspected Lynch syndrome have been proposed. One such approach (",
"    <a class=\"graphic graphic_algorithm graphicRef75385 \" href=\"UTD.htm?18/49/19218\">",
"     algorithm 1",
"    </a>",
"    ) is based on identifying high risk individuals by their clinical features followed by tumor testing for MSI and IHC and selective germline in those with microsatellite unstable tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/56\">",
"     56",
"    </a>",
"    ]. The algorithm was designed primarily for use in colorectal cancers recognizing that microsatellite instability testing has not been as well studied in other Lynch-related tumors.",
"   </p>",
"   <p>",
"    Genetic counseling is offered to patients with Lynch-related tumors who fulfill the Bethesda criteria. Cancers are then tested for microsatellite instability by PCR and for loss of MMR proteins by IHC. Patients with microsatellite unstable tumors by these tests are offered germline testing for MMR gene mutations guided by the IHC results (which describe the MMR protein lost in the tumor). If the gene test is positive, a diagnosis of Lynch syndrome is made and the patient and their family members are referred for genetic counseling and management.",
"   </p>",
"   <p>",
"    Patients with microsatellite unstable tumors and negative germline testing would most commonly be due to hypermethylation of MLH1; thus, tumors with loss of MLH1 by IHC undergo either direct tests for methylation of MLH1 or BRAF mutational testing to identify the sporadic microsatellite unstable cancers.",
"   </p>",
"   <p>",
"    The remaining group of patients without germline mutations who had MSI-H tumors (those with MLH1 loss without MLH1 hypermethylation or BRAF mutation, or those with MSH2 or MSH6 loss) would most likely be due to an undetectable MMR mutation and would be presumed to have Lynch syndrome. In some patients, tumor testing is not feasible and proceeding directly to gene testing is an option if the clinical suspicion of Lynch syndrome is strong. Similarly, if a patient meets the Amsterdam criteria, some experts recommend proceeding directly to gene testing.",
"   </p>",
"   <p>",
"    There are a number of variations on this type of algorithmic approach that could be used. Some laboratories use an age cutoff of 60 years rather than 50 years for routine screening of tumors for microsatellite instability, and some screen the tumors of high risk patients with IHC and further test the cancers that have lost MLH1 for BRAF mutations and only proceed to germline MMR gene testing in patients with loss of MSH2 or MSH6 and the subset of those with MLH1 loss that do not have BRAF mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Predictive models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictive models have been developed in attempts to improve upon the Amsterdam or Bethesda criteria and to provide quantitative estimates of the likelihood of an individual with a MMR mutation, which will be described further below [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Only a few studies have directly compared them [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/57,59,60\">",
"     57,59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One such study (that focused on 725 patients who had undergone genetic testing, 18 of whom had a genetic variation associated with Lynch syndrome) concluded that all four models tested (Leiden, MMRpredict, MMR pro, PREMM",
"      <sub>",
"       1,2",
"      </sub>",
"      ) performed better than the revised Bethesda criteria and that of the predictive models, MMRpredict model performed best [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study included only eight mutation carriers precluding statistical comparisons among the models evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third small study (only eight mutation carriers) compared three of the models (MMRpredict, PREMM",
"      <sub>",
"       1,2",
"      </sub>",
"      , and MMRpro) and found that all of the models had the same sensitivity (75 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/60\">",
"       60",
"      </a>",
"      ]. In addition, the models did not provide better discrimination than the revised Bethesda guidelines (",
"      <a class=\"graphic graphic_table graphicRef72965 \" href=\"UTD.htm?41/48/42763\">",
"       table 4",
"      </a>",
"      ), and all approaches failed to identify two of the eight probands with Lynch syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data are needed to determine the role of these models for the identification of patients with Lynch syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     MMRpredict model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MMRpredict model includes sex, age at diagnosis of colorectal cancer, location of the tumor (proximal versus distal), multiple colorectal cancers (synchronous or metachronous), occurrence of endometrial cancer in any first-degree relatives and occurrence and age at diagnosis of colorectal cancer in first-degree relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/57\">",
"     57",
"    </a>",
"    ]. In a validation study involving 725 consecutive patients with colorectal cancer whose DNA mismatch repair status was available, sensitivity was 94 percent (95% CI 73-99 percent) and specificity was 91 percent (95% CI 88-93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/61\">",
"     61",
"    </a>",
"    ]. The model had better test characteristics compared with the Leiden, MMRpro, and PREMM models (described below). A calculator for this model is available at",
"    <a class=\"external\" href=\"file://hnpccpredict.hgu.mrc.ac.uk/\">",
"     hnpccpredict.hgu.mrc.ac.uk/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Leiden model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Leiden model was developed to generate, for the first time, a quantitative estimate of the likelihood of an individual having a mutation in MSH2 and MLH1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/62\">",
"     62",
"    </a>",
"    ]. The authors used logistic regression to devise a relatively simple model using the mean age of diagnosis of colorectal cancer in the family, the presence or absence of endometrial cancer in the family, and whether the family met the Amsterdam criteria to estimate risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     MMRpro model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MMRpro model uses the personal history and family history of colorectal and endometrial cancer, age of diagnosis (or current age in unaffected family members) and the results of molecular testing for mismatch repair and previous germline testing results (when it is available) to determine the probability of a person having a deleterious germline mutation in the MLH1, MSH2, or MSH6 genes. The model also provides an estimate of future cancer risk in unaffected persons, including mutation carriers, untested persons, and those in whom no mutation is found. It takes into account colorectal cancer, endometrial cancer, and MSI status, but it does not include other Lynch syndrome associated cancers. Validation studies have found that it has better discriminatory ability compared with the Bethesda guidelines and the Leiden model [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/63\">",
"     63",
"    </a>",
"    ]. The MMRpro model can be accessed at",
"    <a class=\"external\" href=\"file://www4.utsouthwestern.edu/breasthealth/cagene/\">",
"     www4.utsouthwestern.edu/breasthealth/cagene/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     PREMM model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PREMM",
"    <sub>",
"     1,2",
"    </sub>",
"    model was originally developed as a predictive algorithm to detect presence of MLH1 or MSH2 mutations based upon the personal history and family history of colorectal cancer, endometrial cancer, and age information similar to that used in the MMRpro model, but information about other HNPCC cancers is also incorporated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/58\">",
"     58",
"    </a>",
"    ]. When a low cutoff for the prediction of a mutation (5 percent or greater) was used in one study, the model had a sensitivity of 100 percent, a specificity of 68 percent, and a positive predictive value of 2 percent for detecting individuals with a mutation in MLH1 or MSH2 mutations. When used in combination with tumor MMR testing, the sensitivity remained 100 percent but the specificity increased to 97 percent and the positive predictive value increased to 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/64\">",
"     64",
"    </a>",
"    ]. The original model does not give a value for the likelihood of MSH6 or PMS2 mutations.",
"   </p>",
"   <p>",
"    The model was then expanded to include MSH6 mutations (the PREMM",
"    <sub>",
"     1,2,6",
"    </sub>",
"    model) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/65\">",
"     65",
"    </a>",
"    ]. Variables included in the model include proband sex, and personal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history (including age at diagnosis) of colorectal cancer, endometrial cancer, or other Lynch syndrome associated cancers. The model provides an estimate of the likelihood that the patient has an MLH1, MSH2, or MSH6 mutation, along with the probability for each individual mutation. Using a cutoff for the predicted risk of mutation of 5 percent, the test had a sensitivity of 94 percent and a specificity of 56 percent. If the cutoff was increased to 40 percent, the sensitivity dropped to 35 percent, but the specificity increased to 97 percent. The PREMM",
"    <sub>",
"     1,2,6",
"    </sub>",
"    model is available at",
"    <a class=\"external\" href=\"file://www.dana-farber.org/pat/cancer/gastrointestinal/crc-calculator/default.asp\">",
"     www.dana-farber.org/pat/cancer/gastrointestinal/crc-calculator/default.asp",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The authors of a validation study of the PREMM",
"    <sub>",
"     1,2",
"    </sub>",
"    model suggest that if the estimated risk of having a deleterious MMR variation is lower than 5 percent, no further steps are recommended. If it is between 5 and 19 percent, they recommend tumor testing for MSI and IHC, and if it is greater than 20 percent, they recommend tumor testing for MSI and IHC with consideration of genetic testing if tumor sample is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/64\">",
"     64",
"    </a>",
"    ]. A cost-effectiveness analysis using the PREMM",
"    <sub>",
"     1,2",
"    </sub>",
"    model found that if risk assessment was started between the ages of 25 and 35, followed by genetic testing for those whose risk was higher than 5 percent, then the cost-effectiveness ratio was $26,000 for every quality adjusted life-year (QALY) gained [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/66\">",
"     66",
"    </a>",
"    ]. This ratio is comparable to those of current cancer screening tests (eg, $35,000 to $165,000 per QALY for breast cancer screening or &lt;$14,000 per QALY for colon cancer screening).",
"   </p>",
"   <p>",
"    One of the advantages of the quantitative models is that the threshold for sensitivity or specificity of the model can be adjusted based upon the clinical situation. High risk clinics that are evaluating patients specifically referred because of a concern of Lynch syndrome might be willing to accept a lower specificity to achieve a high sensitivity and to be sure not to miss patients with the syndrome.",
"   </p>",
"   <p>",
"    These models use different data and can give a rather wide range of mutation-likelihood estimates in the same patient. The models are used in some clinics to provide a range of estimates to help a patient decide whether to proceed with gene testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EXPECTED PREVALENCE OF LYNCH MUTATIONS BASED ON CLINICAL CRITERIA AND MSI STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of detecting Lynch syndrome based upon the clinical history and MSI status was estimated in a study involving families referred for genetic counseling due to a family or personal history of at least one family member with colon cancer diagnosed before the age of 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/67\">",
"     67",
"    </a>",
"    ]. Approximately 70 percent of the families that met the Amsterdam criteria had a known disease-causing MMR mutation, but the frequency varied based upon whether one or more MSI-H tumors were identified in the family. MMR mutations were found in 88 percent of families meeting Amsterdam criteria with tumors demonstrating MSI and, surprisingly, in 29 percent (5 of 17) of the Amsterdam families with microsatellite stable cancers.",
"   </p>",
"   <p>",
"    Interestingly, three of the five MSS tumors in this group showed loss of MMR proteins by IHC arguing in favor of performing both MSI and IHC on tumor blocks. Among families that did not meet the Amsterdam criteria but generally met the Bethesda guidelines, MMR mutations were found in 59 percent of the families with microsatellite unstable cancers and only 3 percent of those with only microsatellite stable tumors. These results generally validate the utility of molecular testing of cancers in patients who meet the Bethesda criteria.",
"   </p>",
"   <p>",
"    Lynch syndrome is less common among young patients with apparently sporadic colorectal cancer. One study examined 75 patients diagnosed with colorectal cancer before the age of 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients were excluded from the analysis if more than one family member had colorectal cancer, but patients were not excluded if they had other Lynch syndrome-associated malignancies. The patients&rsquo; tumors were analyzed using immunohistochemistry for MLH1, MSH2, MSH6, and PMS2. The tumors were also analyzed for MSI and mutations in BRAF and KRAS. Features of Lynch syndrome were identified in only 21 percent of the patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TESTING FOR MUTATIONS IN MISMATCH REPAIR GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once high risk individuals are identified by any of the approaches described above, germline testing is recommended in an affected individual within the family. If possible, the gene test should be performed on one of the family members most likely to have the syndrome (eg, the youngest family member with colorectal cancer). Commercial testing is available for hMSH2, hMLH1, hMSH6, and hPMS2. The cost of gene testing varies depending upon which tests are required as well as the testing method, but complete testing in a new family currently costs approximately $4000. The available assays have high reliability with sensitivities as high as 95 percent. A list of testing laboratories is available through the Genetic Testing Resource (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The finding of a known disease-causing variation in an affected individual establishes the diagnosis of Lynch syndrome and allows testing of the specific mutation in other members of the family with high reliability. However, sometimes the result of gene testing is less clear. Some genetic variants detected during MMR gene testing are of uncertain clinical significance and can make interpretation of the genetic results difficult. Testing laboratories often offer free genetic testing for variants of uncertain significance in other affected family members to aide in determining whether the variant is tracking with cancer in the family, but even these results may be inconclusive. When a variant of uncertain significance is detected, medical management and recommendations are based upon the clinical picture of the family history and the MSI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IHC testing results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     BENEFITS OF GENETIC TESTING FOR LYNCH SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple benefits of genetic testing in high risk families, including a more accurate diagnosis, risk assessment of family members, and more specific targeting of clinical screening and surveillance protocols to gene carriers in the family. Importantly, identification of a germline mutation in a family also allows for reliable identification of family members who did",
"    <strong>",
"     not",
"    </strong>",
"    inherit the mutation and do not need an intensive surveillance program. Family members who do not carry the mutation can be considered to be at similar cancer risk as the general population and thus can be followed using cancer screening guidelines for the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     GENETIC COUNSELING AND INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to genetic testing, practitioners must ensure that the patient or guardian has received appropriate counseling and has provided written informed consent. Genetic counseling recommendations have been issued in a statement from the American Society of Clinical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/69\">",
"     69",
"    </a>",
"    ]. Informed consent should include a general description of the test, its purpose, the disorder to be tested for, the meaning of positive and negative results, and the level of certainty that a positive or negative test is a predictor of disease. Post-test genetic counseling about the risks and benefits of early detection of cancer and available prevention modalities should also be available.",
"   </p>",
"   <p>",
"    Genetic counseling and testing is available through research protocols at many high risk cancer clinics. A partial list of clinics that can provide counseling and genetic testing is available online at:",
"    <a class=\"external\" href=\"file://www.mdacc.tmc.edu/~hcc/Registry.html\">",
"     www.mdacc.tmc.edu/~hcc/Registry.html",
"    </a>",
"    . In addition, the National Society of Genetic Counselors (",
"    <a class=\"external\" href=\"file://www.nsgc.org/\">",
"     www.nsgc.org",
"    </a>",
"    ) has a national listing of genetic counselors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Genetic discrimination legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 2008, the Genetic Information Nondiscrimination Act (GINA) was signed into law in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/59/19386/abstract/70\">",
"     70",
"    </a>",
"    ]. This legislation protects individuals against inappropriate use of their genetic information by health insurers and employers. Fear of employment or health insurance discrimination has been a barrier to pursuing genetic testing for many high risk individuals. Although most states have legislation addressing genetic discrimination and there are several federal laws, such as the Health Insurance Portability and Accountability Act (HIPAA) and Americans with Disabilities Act (ADA), the new GINA law will provide better defined protection. It will ban use of predictive genetic information in underwriting, enrollment, and coverage decisions by group and individual health insurers and in employment-related decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lynch syndrome is an autosomal dominant disorder that is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. It accounts for 2 to 3 percent of all colon cancer cases and similarly is responsible for about 2 percent of uterine cancer.",
"     </li>",
"     <li>",
"      Patients with Lynch syndrome have a markedly increased risk of colorectal and uterine cancer, and several other cancers including ovarian, upper urologic tract, gastric, small bowel,",
"      <span class=\"nowrap\">",
"       biliary/pancreatic,",
"      </span>",
"      skin (sebaceous adenomas and carcinomas and keratoacanthomas), and brain cancers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our general approach is described below. However, individual families are often approached differently depending upon the details of their family history. Furthermore, there are patients who have clinical features that raise suspicion for HNPCC (eg, young age at presentation, poorly differentiated tumors in the right colon, tumors that contain mucin) whose family history may be incomplete but who nevertheless may be at increased risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that patients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      families in whom Lynch syndrome is considered be referred to a genetic counselor preferably in the setting of a high risk cancer clinic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We do not use any of the statistical models described above routinely but will run them in selected cases to give a patient a range of estimates of the likelihood of finding a germline mutation.",
"     </li>",
"     <li>",
"      In our high risk cancer clinic we start by obtaining a three generation family history of all cancers and obtain pathology reports and slides of the critical cancers to confirm the diagnoses, then generally follow an approach similar to that shown in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef75385 \" href=\"UTD.htm?18/49/19218\">",
"       algorithm 1",
"      </a>",
"      ). Our usual approach differs depending on whether the family meets the Amsterdam II criteria or the Bethesda guidelines. As noted above, the optimal testing strategy continues to be debated and alternative strategies may also be acceptable.",
"     </li>",
"     <li>",
"      If the family is suspicious for Lynch syndrome (ie, meets Bethesda or Amsterdam II criteria), we provide genetic counseling and usually recommend IHC or MSI if colon tumor is available. If no tumor is available we would consider direct MMR gene testing in the youngest living member of the family with colorectal cancer if possible. If the gene test shows a known disease-causing MMR gene mutation, gene testing is then offered to the other at-risk members of the family and screening recommendation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the cancer is microsatellite stable, we exclude the diagnosis of Lynch syndrome and recommend screening based upon the strength of the family history. If the cancer is microsatellite unstable and the immunohistochemistry shows loss of MSH2, MSH6 or PMS2, we suggest full genetic counseling and MMR gene testing of the gene suggested to be involved by the immunohistochemistry, unless gene testing had already been done from a family that met Amsterdam criteria (see above).",
"     </li>",
"     <li>",
"      If the cancer is microsatellite unstable and immunohistochemistry shows loss of MLH1, we suggest BRAF mutation testing and proceed with counseling and gene testing only if there was no BRAF mutation; if BRAF mutation is present, it indicates that the microsatellite instability is due to hypermethylation of MLH1 rather than Lynch syndrome. If gene testing is negative under these conditions (MSI tumors with loss of MSH2, MSH6, PMS2, or MLH1 without BRAF mutation), we consider the gene test as uninformative and suggest screening of all at-risk family members as if the family had Lynch syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/1\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/2\">",
"      Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/3\">",
"      Lin KM, Shashidharan M, Ternent CA, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 1998; 41:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/4\">",
"      Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/5\">",
"      Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/6\">",
"      Vasen HF, M&ouml;slein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/7\">",
"      Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007; 133:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/8\">",
"      Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/9\">",
"      Sankila R, Aaltonen LA, J&auml;rvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/10\">",
"      Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/11\">",
"      Obermair A, Youlden DR, Young JP, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010; 127:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/12\">",
"      Mecklin JP, J&auml;rvinen HJ. Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 1991; 68:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/13\">",
"      Soravia C, van der Klift H, Br&uuml;ndler MA, et al. Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 2003; 121A:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/14\">",
"      Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/15\">",
"      Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012; 104:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/16\">",
"      Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30:4409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/17\">",
"      Buerki N, Gautier L, Kovac M, et al. Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 2012; 51:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/18\">",
"      South CD, Hampel H, Comeras I, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008; 100:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/19\">",
"      Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/20\">",
"      Wu Y, Berends MJ, Sijmons RH, et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001; 29:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/21\">",
"      Koessler T, Oestergaard MZ, Song H, et al. Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008; 57:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/22\">",
"      Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011; 12:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/23\">",
"      Tannerg&aring;rd P, Lipford JR, Kolodner R, et al. Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families. Cancer Res 1995; 55:6092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/24\">",
"      Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/25\">",
"      Bonadona V, Bona&iuml;ti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/26\">",
"      Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/27\">",
"      Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/28\">",
"      Ricciardone MD, Oz&ccedil;elik T, Cevher B, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 1999; 59:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/29\">",
"      Whiteside D, McLeod R, Graham G, et al. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple caf&eacute;-au-lait spots. Cancer Res 2002; 62:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/30\">",
"      Bougeard G, Charbonnier F, Moerman A, et al. Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003; 72:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/31\">",
"      Gallinger S, Aronson M, Shayan K, et al. Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 2004; 126:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/32\">",
"      Menko FH, Kaspers GL, Meijer GA, et al. A homozygous MSH6 mutation in a child with caf&eacute;-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer 2004; 3:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/33\">",
"      Nakagawa H, Lockman JC, Frankel WL, et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004; 64:4721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/34\">",
"      Truninger K, Menigatti M, Luz J, et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005; 128:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/35\">",
"      Worthley DL, Walsh MD, Barker M, et al. Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer. Gastroenterology 2005; 128:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/36\">",
"      Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet 2007; 71:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/37\">",
"      Will O, Carvajal-Carmona LG, Gorman P, et al. Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. Gastroenterology 2007; 132:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/38\">",
"      Clendenning M, Senter L, Hampel H, et al. A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. J Med Genet 2008; 45:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/39\">",
"      Lynch HT, Lynch JF, Lynch PM. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J Natl Cancer Inst 2007; 99:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/40\">",
"      Bessa X, Alenda C, Paya A, et al. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. J Clin Oncol 2011; 29:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/41\">",
"      Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review. J Genet Couns 2011; 20:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/42\">",
"      Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/43\">",
"      Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26:5783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/44\">",
"      Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2011; 13:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/45\">",
"      Yurgelun MB, Goel A, Hornick JL, et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) 2012; 5:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/46\">",
"      Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/47\">",
"      Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/48\">",
"      Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001; 69:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/49\">",
"      Percesepe A, Borghi F, Menigatti M, et al. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 2001; 19:3944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/50\">",
"      Ravnik-Glavac M, Potocnik U, Glavac D. Incidence of germline hMLH1 and hMSH2 mutations (HNPCC patients) among newly diagnosed colorectal cancers in a Slovenian population. J Med Genet 2000; 37:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/51\">",
"      Juli&eacute; C, Tr&eacute;sallet C, Brouquet A, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008; 103:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/52\">",
"      Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012; 30:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/53\">",
"      Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/54\">",
"      Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/55\">",
"      Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011; 155:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/56\">",
"      Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/57\">",
"      Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/58\">",
"      Balma&ntilde;a J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006; 296:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/59\">",
"      Balma&ntilde;a J, Balaguer F, Castellv&iacute;-Bel S, et al. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008; 45:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/60\">",
"      Tresallet C, Brouquet A, Juli&eacute; C, et al. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. Int J Cancer 2012; 130:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/61\">",
"      Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009; 101:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/62\">",
"      Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998; 339:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/63\">",
"      Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/64\">",
"      Balaguer F, Balma&ntilde;a J, Castellv&iacute;-Bel S, et al. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 2008; 134:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/65\">",
"      Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011; 140:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/66\">",
"      Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 2011; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/67\">",
"      Lagerstedt Robinson K, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007; 99:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/68\">",
"      Goel A, Nagasaka T, Spiegel J, et al. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clin Gastroenterol Hepatol 2010; 8:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/69\">",
"      Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/59/19386/abstract/70\">",
"      Leib JR, Hoddfar E, Larsen Haidle J, et al. The new genetic privacy law. Community Oncology 2008; 5:351.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2605 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19386=[""].join("\n");
var outline_f18_59_19386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Colorectal cancers in Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Extracolonic cancers in Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Muir-Torre and Turcot variants of Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENETICS OF LYNCH SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      The mismatch repair (MMR) system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Consequences of the defective mismatch repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Genotype/phenotype associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biallelic MMR deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Microsatellite instability: The molecular signature of Lynch syndrome cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IDENTIFICATION OF INDIVIDUALS WITH LYNCH SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Amsterdam criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bethesda guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Universal testing strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Algorithms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Predictive models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - MMRpredict model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Leiden model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - MMRpro model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - PREMM model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EXPECTED PREVALENCE OF LYNCH MUTATIONS BASED ON CLINICAL CRITERIA AND MSI STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TESTING FOR MUTATIONS IN MISMATCH REPAIR GENES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      BENEFITS OF GENETIC TESTING FOR LYNCH SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      GENETIC COUNSELING AND INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Genetic discrimination legislation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2605|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/49/19218\" title=\"algorithm 1\">",
"      Testing algorithm for Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2605|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/24/27011\" title=\"picture 1\">",
"      Familial colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/25/19869\" title=\"table 1\">",
"      Cancer risk Lynch genotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/17/29981\" title=\"table 2\">",
"      IHC interpretation for mismatch repair genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/37/3675\" title=\"table 3\">",
"      Revised Amsterdam criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42763\" title=\"table 4\">",
"      Revised Bethesda criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/50/15148\" title=\"table 5\">",
"      MSI testing Bethesda",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_59_19387="NCI CTCAE Heart Failure";
var content_f18_59_19387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria for Adverse Events grading scale for heart failure (v4.0)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Asymptomatic with laboratory (eg, B-Natriuretic Peptide) or cardiac imaging abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Symptoms with mild to moderate activity or exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Severe symptoms at rest or with minimal activity or exertion; intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated (eg, continuous IV therapy or mechanical hemodynamic support)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute. Available at:",
"     <a href=\"file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\">",
"      file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19387=[""].join("\n");
var outline_f18_59_19387=null;
var title_f18_59_19388="Indicator conditions in AIDS";
var content_f18_59_19388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indicator conditions in case definition of AIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Candidiasis of esophagus, trachea, bronchi, or lungs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cervical cancer, invasive*&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coccidioidomycosis, extrapulmonary*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryptococcosis, extrapulmonary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryptosporidiosis with diarrhea for &gt;1 month",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytomegalovirus of any organ other than liver, spleen, or lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes simplex with mucocutaneous ulcer for &gt;1 month or bronchitis, pneumonitis, esophagitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histoplasmosis, extrapulmonary*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV-associated dementia: disabling cognitive and/or motor dysfunction interfering with occupation or activities of daily living",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV-associated wasting*: involuntary weight loss of &gt;10 percent of baseline plus chronic diarrhea (&ge;2 loose stools/day for &ge;30 days) or chronic weakness and documented enigmatic fever for &ge;30 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isosporosis with diarrhea for &gt;1 month*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kaposi's sarcoma in patient younger than age 60 (or older than age 60*)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoma of brain in patient younger than age 60 (or older than age 60*)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoma, non-Hodgkin's of B cell or unknown immunologic phenotype and histology showing small, noncleaved lymphoma or immunoblastic sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium avium or M. kansasii, disseminated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium tuberculosis, disseminated*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium tuberculosis, pulmonary*&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocardiosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumocystis carinii (P jiroveci) pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumonia, recurrent-bacteria*&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Progressive multifocal leukoencephalopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salmonella septicemia (nontyphoid), recurrent*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Strongyloidosis, extraintestinal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toxoplasmosis of internal organ",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Requires positive HIV serology.",
"     <br>",
"      &bull; Added in the revised case definition 1993.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19388=[""].join("\n");
var outline_f18_59_19388=null;
var title_f18_59_19389="CF enteral formulas";
var content_f18_59_19389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Enteral formulas used for individuals with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Formula",
"       </td>",
"       <td class=\"subtitle1\">",
"        Company",
"       </td>",
"       <td class=\"subtitle1\">",
"        MCT, as percent of kcals from fat",
"       </td>",
"       <td class=\"subtitle1\">",
"        kCal/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Osmolarity, mOsm/kg water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregestimil",
"       </td>",
"       <td>",
"        Mead-Johnson",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        Hydrolyzed casein",
"       </td>",
"       <td>",
"        320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptamen Junior",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        Hydrolyzed whey",
"       </td>",
"       <td>",
"        260 (unflavored)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptamen Junior 1.5&nbsp;",
"       </td>",
"       <td>",
"        Nestle&nbsp;",
"       </td>",
"       <td>",
"        60&nbsp;",
"       </td>",
"       <td>",
"        1.5&nbsp;",
"       </td>",
"       <td>",
"        Hydrolyzed whey&nbsp;",
"       </td>",
"       <td>",
"        450&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptamen",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        Hydrolyzed whey",
"       </td>",
"       <td>",
"        270 (unflavored)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <table cellspacing=\"0\">",
"         <tbody>",
"         </tbody>",
"        </table>",
"        Pediasure Peptide&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Abbott&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        50&nbsp;",
"       </td>",
"       <td>",
"        1.0&nbsp;",
"       </td>",
"       <td>",
"        Hydrolyzed whey&nbsp;",
"       </td>",
"       <td>",
"        250 (unflavored)&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediasure Peptide 1.5&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        50&nbsp;",
"       </td>",
"       <td>",
"        1.5&nbsp;",
"       </td>",
"       <td>",
"        Hydrolyzed whey, hydrolyzed casein&nbsp;",
"       </td>",
"       <td>",
"        450&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two Cal HN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        20&nbsp;",
"       </td>",
"       <td>",
"        2.0&nbsp;",
"       </td>",
"       <td>",
"        Caseinate&nbsp;",
"       </td>",
"       <td>",
"        730 (flavored)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutren 1.5",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        Caseinate",
"       </td>",
"       <td>",
"        430 (unflavored)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutren 2.0",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        Caseinate",
"       </td>",
"       <td>",
"        745",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elecare Infant",
"       </td>",
"       <td>",
"        Abbott",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        Free amino acids",
"       </td>",
"       <td>",
"        350",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Elecare Junior&nbsp;",
"        </p>",
"        <p>",
"         (unflavored/vanilla)&nbsp;&nbsp;&nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        33&nbsp;",
"       </td>",
"       <td>",
"        1.0&nbsp;",
"       </td>",
"       <td>",
"        Free amino acids&nbsp;",
"       </td>",
"       <td>",
"        590",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neocate Infant",
"       </td>",
"       <td>",
"        Nutricia",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        Free amino acids",
"       </td>",
"       <td>",
"        375",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Neocate Junior",
"        </p>",
"        <p>",
"         (unflavored/vanilla)",
"        </p>",
"       </td>",
"       <td>",
"        Nutricia",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        Free amino acids",
"       </td>",
"       <td>",
"        590",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vivonex Pediatric",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        Free amino acids",
"       </td>",
"       <td>",
"        360",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCT: medium-chain triglycerides; kcal: kilocalories.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Pediatric Nutrition for Patients with Cystic Fibrosis. Consensus Conference: Concepts in CF Care 2001; 10:31. Copyright &copy; 2001 Cystic Fibrosis Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19389=[""].join("\n");
var outline_f18_59_19389=null;
var title_f18_59_19390="Contents: Tick flea mite louse borne infections";
var content_f18_59_19390=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Tick flea mite louse borne infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Tick flea mite louse borne infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bacterial infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/15/11512\">",
"           Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/21/31062\">",
"           Epidemiology of yersiniosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24774\">",
"           Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lyme disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/25/35225\">",
"           Clinical manifestations of Lyme disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28425\">",
"           Diagnosis of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/29/41431\">",
"           Epidemiology of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26263\">",
"           Evaluation of a tick bite for possible Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26552\">",
"           Immunopathogenesis of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40759\">",
"           Lyme carditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/22/42342\">",
"           Microbiology of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9336\">",
"           Musculoskeletal manifestations of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/21/14681\">",
"           Nervous system Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/55/3960\">",
"           Prevention of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27498\">",
"           Treatment of Lyme disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/2/28712\">",
"           Scabies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other spirochetal infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/43/15033\">",
"           Clinical features, diagnosis, and management of relapsing fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39336\">",
"           Microbiology, pathogenesis, and epidemiology of relapsing fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/58/26533\">",
"           Southern tick-associated rash illness (STARI)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoan disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/25/39321\">",
"           Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/16/42248\">",
"           Epidemiology and pathogenesis of babesiosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rickettsial infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31364\">",
"           Biology of Rickettsia rickettsii infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/62/23525\">",
"           Biology of ehrlichiae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/51/14135\">",
"           Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/46/21219\">",
"           Diagnosis and treatment of murine typhus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/29/38358\">",
"           Epidemic typhus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/5/6234\">",
"           Human ehrlichiosis and anaplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/8/28808\">",
"           Other spotted fever group rickettsial infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29220\">",
"           Rickettsialpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/6/18534\">",
"           Scrub typhus: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/14/26852\">",
"           Scrub typhus: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/9/27796\">",
"           The epidemiology and clinical manifestations of murine typhus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14725\">",
"           Treatment of Rocky Mountain spotted fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Toxic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/26/3494\">",
"           Tick paralysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral CNS infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38760\">",
"           Arthropod-borne encephalitides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16088\">",
"           Epidemiology and pathogenesis of West Nile virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/8/38023\">",
"           St. Louis encephalitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-513B0CBE5E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_59_19390=[""].join("\n");
var outline_f18_59_19390=null;
var title_f18_59_19391="UGI duodenal bulb";
var content_f18_59_19391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Upper gastrointestinal contrast studies demonstrating the duodenal bulb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the image on the left, the duodenal bulb is to left of the spine. In the image on the right, with malrotation, the duodenal bulb is overlying spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Carlo Buonomo, MD, Children's Hospital-Boston. Copyright &copy; Carlo Buonomo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_59_19391=[""].join("\n");
var outline_f18_59_19391=null;
